{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [],
   "source": [
    "import sys\n",
    "from os import listdir\n",
    "import numpy as np \n",
    "from xml.dom.minidom import parse\n",
    "from nltk.tokenize import word_tokenize\n",
    "from nltk.corpus import stopwords\n",
    "stopwords =  set(stopwords.words('english'))\n",
    "import pandas as pd\n",
    "output_path_name=\"task9.2_raquel_5.txt\"\n",
    "\n",
    "output_path =  \"evaluations/\" + output_path_name\n",
    "results_path = output_path.replace('.txt', '_All_scores.log')\n",
    "datadir = '../../data/Test-DDI/DrugBank'\n",
    "training_data = '/home/raquel/Documents/mai/ahlt/data/Train/All'"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "SCORES FOR THE GROUP: raquel RUN=5\n",
      "Gold Dataset: /DrugBank\n",
      "\n",
      "Partial Evaluation: only detection of DDI (regadless to the type)\n",
      "tp\tfp\tfn\ttotal\tprec\trecall\tF1\n",
      "533\t2090\t351\t884\t0.2032\t0.6029\t0.304\n",
      "\n",
      "\n",
      "Detection and Classification of DDI\n",
      "tp\tfp\tfn\ttotal\tprec\trecall\tF1\n",
      "212\t2411\t672\t884\t0.0808\t0.2398\t0.1209\n",
      "\n",
      "\n",
      "________________________________________________________________________\n",
      "\n",
      "SCORES FOR DDI TYPE\n",
      "Scores for ddi with type mechanism\n",
      "tp\tfp\tfn\ttotal\tprec\trecall\tF1\n",
      "77\t776\t201\t278\t0.0903\t0.277\t0.1362\n",
      "\n",
      "\n",
      "Scores for ddi with type effect\n",
      "tp\tfp\tfn\ttotal\tprec\trecall\tF1\n",
      "113\t645\t185\t298\t0.1491\t0.3792\t0.214\n",
      "\n",
      "\n",
      "Scores for ddi with type advise\n",
      "tp\tfp\tfn\ttotal\tprec\trecall\tF1\n",
      "22\t990\t192\t214\t0.0217\t0.1028\t0.0359\n",
      "\n",
      "\n",
      "Scores for ddi with type int\n",
      "tp\tfp\tfn\ttotal\tprec\trecall\tF1\n",
      "0\t0\t94\t94\t0\t0\t0\n",
      "\n",
      "\n",
      "MACRO-AVERAGE MEASURES:\n",
      "\tP\tR\tF1\n",
      "\t0.0653\t0.1897\t0.0971\n",
      "________________________________________________________________________\n",
      "\n",
      "\n"
     ]
    }
   ],
   "source": [
    "interaction_words = ['interacts', 'enhances', 'inhibits']\n",
    "def check_interaction(tokens, entities, e1, e2):\n",
    "    # Complete this function to return a pair (boolean, ddi_type)\n",
    "    # depending on whether there is an interaction between e1 and e2\n",
    "    token_list = [t[0] for t in tokens]\n",
    "    # print(token_list,'\\n', entities,'\\n', e1,'\\n', e2)\n",
    "    \n",
    "    if 'increase' in token_list or 'increased' in token_list: \n",
    "        return True, 'mechanism'\n",
    "    \n",
    "    if 'effect' in token_list or 'effects' in token_list: \n",
    "        return True, 'effect'\n",
    "    \n",
    "    if 'patients' and 'may' in token_list:\n",
    "        return True, 'advise'\n",
    "    \n",
    "    if 'may' in token_list:\n",
    "        return True, 'mechanism'\n",
    "    return False, \"null\"\n",
    "\n",
    "def tokenize(txt):\n",
    "    offset = 0\n",
    "    tks = []\n",
    "    for t in word_tokenize(txt):\n",
    "        offset = txt.find(t, offset)\n",
    "        tks.append((t, offset, offset + len(t) - 1))\n",
    "        offset += len(t)\n",
    "    return tks\n",
    "\n",
    "\n",
    "#datadir = sys.argv[1]\n",
    "\n",
    "def predict(datadir,output_path,test=False):\n",
    "    # process each file in directory\n",
    "    with open(output_path, 'w') as file:\n",
    "        for f in listdir(datadir):\n",
    "\n",
    "            # parse XML file, obtaining a DOM tree\n",
    "            tree = parse(datadir + \"/\" + f)\n",
    "\n",
    "            # process each sentence in the file\n",
    "            sentences = tree.getElementsByTagName(\"sentence\")\n",
    "            for s in sentences:\n",
    "                sid = s.attributes[\"id\"].value  # get sentence id\n",
    "                stext = s.attributes[\"text\"].value  # get sentence text\n",
    "\n",
    "                tokens = tokenize(stext)\n",
    "\n",
    "                # load sentence entities\n",
    "                entities = {}\n",
    "                ents = s.getElementsByTagName(\"entity\")\n",
    "                for e in ents:\n",
    "                    id = e.attributes[\"id\"].value\n",
    "                    offs = e.attributes[\"charOffset\"].value.split(\"-\")\n",
    "                    entities[id] = offs\n",
    "\n",
    "                # for each pair in the sentence, decide whether it is DDI and its type\n",
    "                pairs = s.getElementsByTagName(\"pair\")\n",
    "                for p in pairs:\n",
    "                    id_e1 = p.attributes[\"e1\"].value\n",
    "                    id_e2 = p.attributes[\"e2\"].value\n",
    "                    (is_ddi, ddi_type) = check_interaction(tokens, entities, id_e1, id_e2)                    \n",
    "                    ddi = \"1\" if is_ddi else \"0\"\n",
    "                    file.write(sid + \"|\" + id_e1 + \"|\" + id_e2 + \"|\" + ddi + \"|\" + ddi_type)\n",
    "                    file.write('\\n')\n",
    "                    if test:\n",
    "                        return\n",
    "\n",
    "def show_results(results_path):\n",
    "    import subprocess\n",
    "    subprocess.call(['java', '-jar', '../../eval/evaluateDDI.jar', '../../data/Test-DDI/DrugBank', output_path])\n",
    "    results_file = open(results_path,'r')\n",
    "    print(results_file.read())\n",
    "    results_file.close()\n",
    "\n",
    "predict(datadir,output_path,False)\n",
    "show_results(results_path)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "mechanism: Aminoglutethimide administered concomitantly depo-subQ provera 104\n",
      "effect: ProAmatine , cardiac glycosides\n",
      "effect: phenylephrine , pseudoephedrine , ephedrine , phenylpropanolamine dihydroergotamine ) may enhance potentiate pressor effects ProAmatine\n",
      "effect: pseudoephedrine , ephedrine , phenylpropanolamine dihydroergotamine ) may enhance potentiate pressor effects ProAmatine\n",
      "effect: ephedrine , phenylpropanolamine dihydroergotamine ) may enhance potentiate pressor effects ProAmatine\n",
      "effect: phenylpropanolamine dihydroergotamine ) may enhance potentiate pressor effects ProAmatine\n",
      "effect: dihydroergotamine ) may enhance potentiate pressor effects ProAmatine\n",
      "effect: Alpha-adrenergic blocking agents , prazosin , terazosin , doxazosin , antagonize effects ProAmatine\n",
      "effect: prazosin , terazosin , doxazosin , antagonize effects ProAmatine\n",
      "effect: terazosin , doxazosin , antagonize effects ProAmatine\n",
      "effect: doxazosin , antagonize effects ProAmatine\n",
      "mechanism: desglymidodrine ( base ) due active tubular secretion base-secreting system also responsible secretion drugs metformin\n",
      "mechanism: desglymidodrine ( base ) due active tubular secretion base-secreting system also responsible secretion drugs metformin , cimetidine\n",
      "mechanism: desglymidodrine ( base ) due active tubular secretion base-secreting system also responsible secretion drugs metformin , cimetidine , ranitidine\n",
      "mechanism: desglymidodrine ( base ) due active tubular secretion base-secreting system also responsible secretion drugs metformin , cimetidine , ranitidine , procainamide\n",
      "mechanism: desglymidodrine ( base ) due active tubular secretion base-secreting system also responsible secretion drugs metformin , cimetidine , ranitidine , procainamide , triamterene\n",
      "mechanism: desglymidodrine ( base ) due active tubular secretion base-secreting system also responsible secretion drugs metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide\n",
      "mechanism: desglymidodrine ( base ) due active tubular secretion base-secreting system also responsible secretion drugs metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , quinidine\n",
      "advise: Ropivacaine used caution patients receiving local anesthetics\n",
      "mechanism: ropivacaine reduced 70 % coadministration fluvoxamine\n",
      "int: fluvoxamine , given concomitantly administration Ropivacaine\n",
      "mechanism: ketoconazole ( 100 mg bid 2 days ropivacaine infusion administered 1 hour ketoconazole ) caused 15 % reduction in-vivo plasma clearance ropivacaine\n",
      "mechanism: megestrol acetate indinavir\n",
      "advise: indinavir considered coadministering megestrol acetate\n",
      "int: coumarin-type anticoagulants reported FELDENE\n",
      "advise: FELDENE patients coumarin-type anticoagulants\n",
      "mechanism: FELDENE administered conjunction aspirin\n",
      "mechanism: Nonsteroidal anti-inflammatory agents , including FELDENE , reported increase steady state plasma lithium\n",
      "mechanism: FELDENE , reported increase steady state plasma lithium\n",
      "advise: lithium levels monitored initiating , adjusting discontinuing FELDENE\n",
      "mechanism: folic acid digoxin reported agents administered concomitantly sulfasalazine\n",
      "mechanism: digoxin reported agents administered concomitantly sulfasalazine\n",
      "effect: Sanctura anticholinergic agents\n",
      "mechanism: Sanctura potential pharmacokinetic interactions drugs eliminated active tubular secretion ( e.g . digoxin\n",
      "mechanism: Sanctura potential pharmacokinetic interactions drugs eliminated active tubular secretion ( e.g . digoxin , procainamide\n",
      "mechanism: Sanctura potential pharmacokinetic interactions drugs eliminated active tubular secretion ( e.g . digoxin , procainamide , pancuronium\n",
      "mechanism: Sanctura potential pharmacokinetic interactions drugs eliminated active tubular secretion ( e.g . digoxin , procainamide , pancuronium , morphine\n",
      "mechanism: Sanctura potential pharmacokinetic interactions drugs eliminated active tubular secretion ( e.g . digoxin , procainamide , pancuronium , morphine , vancomycin\n",
      "mechanism: Sanctura potential pharmacokinetic interactions drugs eliminated active tubular secretion ( e.g . digoxin , procainamide , pancuronium , morphine , vancomycin , metformin\n",
      "mechanism: Sanctura potential pharmacokinetic interactions drugs eliminated active tubular secretion ( e.g . digoxin , procainamide , pancuronium , morphine , vancomycin , metformin tenofovir\n",
      "mechanism: phenobarbital , phenytoin rifampin may increase clearance corticosteroids\n",
      "mechanism: phenobarbital , phenytoin rifampin may increase clearance corticosteroids may require increases corticosteroid\n",
      "mechanism: phenytoin rifampin may increase clearance corticosteroids\n",
      "mechanism: phenytoin rifampin may increase clearance corticosteroids may require increases corticosteroid\n",
      "mechanism: rifampin may increase clearance corticosteroids\n",
      "mechanism: rifampin may increase clearance corticosteroids may require increases corticosteroid\n",
      "mechanism: troleandomycin ketoconazole may inhibit metabolism corticosteroids\n",
      "mechanism: ketoconazole may inhibit metabolism corticosteroids\n",
      "mechanism: Corticosteroids may increase clearance chronic high dose aspirin\n",
      "effect: salicylate toxicity corticosteroid\n",
      "advise: Aspirin used cautiously conjunction corticosteroids\n",
      "effect: corticosteroids oral anticoagulants\n",
      "effect: anticoagulants given concurrently corticosteroids\n",
      "advise: short-acting beta adrenergic aerosol bronchodilators used concomitantly MAXAIR AUTOHALER\n",
      "advise: DEMSER patients receiving phenothiazines\n",
      "advise: DEMSER patients receiving phenothiazines haloperidol\n",
      "effect: DEMSER alcohol\n",
      "effect: DEMSER alcohol CNS depressants\n",
      "effect: reserpine ) may additive effect given beta-blocking agents\n",
      "mechanism: Pindolol shown increase serum thioridazine\n",
      "mechanism: TRITEC clarithromycin\n",
      "mechanism: antacid ( 170 mEq ) results 28 % decrease plasma concentrations ranitidine\n",
      "mechanism: antacid ( 170 mEq ) results 28 % decrease plasma concentrations ranitidine may decrease plasma concentrations bismuth TRITEC\n",
      "mechanism: probenecid ) could potentially result delayed clearance ALIMTA\n",
      "advise: ibuprofen concurrently ALIMTA\n",
      "advise: NSAIDs short elimination half-lives period 2 days , day , 2 days following administration ALIMTA\n",
      "advise: NSAIDs interrupt dosing least 5 days , day , 2 days following ALIMTA\n",
      "advise: FLOMAX capsules NOT used combination alpha-adrenergic blocking agents\n",
      "advise: FLOMAX capsules used caution combination cimetidine\n",
      "advise: warfarin FLOMAX\n",
      "effect: CYLERT concomitantly antiepileptic medications\n",
      "effect: DIPRIVAN Injectable Emulsion may reduced patients intramuscular intravenous premedication , particularly narcotics\n",
      "effect: DIPRIVAN Injectable Emulsion may reduced patients intramuscular intravenous premedication , particularly narcotics ( eg , morphine\n",
      "effect: DIPRIVAN Injectable Emulsion may reduced patients intramuscular intravenous premedication , particularly narcotics ( eg , morphine , meperidine\n",
      "effect: DIPRIVAN Injectable Emulsion may reduced patients intramuscular intravenous premedication , particularly narcotics ( eg , morphine , meperidine , fentanyl\n",
      "advise: DIPRIVAN Injectable Emulsion administration adjusted according desired level anesthesia sedation may reduced presence supplemental analgesic agents\n",
      "advise: DIPRIVAN Injectable Emulsion administration adjusted according desired level anesthesia sedation may reduced presence supplemental analgesic agents ( eg , nitrous oxide\n",
      "advise: DIPRIVAN Injectable Emulsion administration adjusted according desired level anesthesia sedation may reduced presence supplemental analgesic agents ( eg , nitrous oxide opioids\n",
      "mechanism: Thiabendazole may compete drugs , theophylline\n",
      "advise: thiabendazole xanthine derivatives\n",
      "mechanism: alcohol ( equivalent 60 g ) minimal effect plasma levels mirtazapine\n",
      "effect: REMERON shown additive produced alcohol\n",
      "advise: alcohol taking REMERON SolTab\n",
      "mechanism: diazepam ( 15 mg ) minimal effect plasma levels mirtazapine\n",
      "effect: REMERON shown additive caused diazepam\n",
      "advise: diazepam similar drugs taking REMERON SolTab\n",
      "effect: TOLECTIN warfarin\n",
      "advise: TOLECTIN patients anticoagulants\n",
      "advise: TOLECTIN administered concomitantly methotrexate\n",
      "mechanism: TOLECTIN nonsteroidal anti-inflammatory drugs reported reduce tubular secretion methotrexate\n",
      "mechanism: nonsteroidal anti-inflammatory drugs reported reduce tubular secretion methotrexate\n",
      "advise: paliperidone , INVEGA used caution combination centrally acting drugs\n",
      "advise: paliperidone , INVEGA used caution combination centrally acting drugs alcohol\n",
      "advise: INVEGA used caution combination centrally acting drugs\n",
      "advise: INVEGA used caution combination centrally acting drugs alcohol\n",
      "effect: Paliperidone may antagonize effect levodopa\n",
      "effect: Paliperidone may antagonize effect levodopa dopamine agonists\n",
      "int: Vitamin B1 ( Thiamine ) : Loop Diuretics\n",
      "int: Vitamin B1 ( Thiamine ) : Loop Diuretics , Oral Contraceptives\n",
      "int: Vitamin B1 ( Thiamine ) : Loop Diuretics , Oral Contraceptives , Stavudine\n",
      "int: Vitamin B1 ( Thiamine ) : Loop Diuretics , Oral Contraceptives , Stavudine , Tricyclic Antidepressants\n",
      "int: Thiamine ) : Loop Diuretics\n",
      "int: Thiamine ) : Loop Diuretics , Oral Contraceptives\n",
      "int: Thiamine ) : Loop Diuretics , Oral Contraceptives , Stavudine\n",
      "int: Thiamine ) : Loop Diuretics , Oral Contraceptives , Stavudine , Tricyclic Antidepressants\n",
      "int: Mequitazine interact CNS depressant\n",
      "int: Mequitazine interact CNS depressant , antichlolinergic\n",
      "int: Mequitazine interact CNS depressant , antichlolinergic , TCA\n",
      "int: Mequitazine interact CNS depressant , antichlolinergic , TCA , MAOIs\n",
      "int: Mequitazine interact CNS depressant , antichlolinergic , TCA , MAOIs , alcohol\n",
      "advise: tigecycline administered warfarin\n",
      "effect: antibacterial drugs oral contraceptives\n",
      "effect: oxycodone hydrochloride may additive CNS\n",
      "effect: Streptase , Streptokinase , alone combination antiplatelet agents\n",
      "effect: Streptase , Streptokinase , alone combination antiplatelet agents anticoagulants\n",
      "effect: Streptokinase , alone combination antiplatelet agents\n",
      "effect: Streptokinase , alone combination antiplatelet agents anticoagulants\n",
      "effect: aspirin Streptokinase\n",
      "advise: Methergine ( methylergonovine maleate ) used concurrently vasoconstrictors\n",
      "advise: Methergine ( methylergonovine maleate ) used concurrently vasoconstrictors ergot alkaloids\n",
      "advise: methylergonovine maleate ) used concurrently vasoconstrictors\n",
      "effect: Triprolidine may enhance sedative effects central nervous system depressants\n",
      "effect: Triprolidine may enhance sedative effects central nervous system depressants including alcohol\n",
      "effect: Triprolidine may enhance sedative effects central nervous system depressants including alcohol , barbiturates\n",
      "effect: Triprolidine may enhance sedative effects central nervous system depressants including alcohol , barbiturates , hypnotics\n",
      "effect: Triprolidine may enhance sedative effects central nervous system depressants including alcohol , barbiturates , hypnotics , narcotic analgesics\n",
      "effect: Triprolidine may enhance sedative effects central nervous system depressants including alcohol , barbiturates , hypnotics , narcotic analgesics , sedatives\n",
      "effect: Triprolidine may enhance sedative effects central nervous system depressants including alcohol , barbiturates , hypnotics , narcotic analgesics , sedatives , tranquillisers\n",
      "effect: anticholinergic drugs , atropine tricyclic antidepressants may enhanced concomitant administration triprolidine\n",
      "effect: atropine tricyclic antidepressants may enhanced concomitant administration triprolidine\n",
      "effect: tricyclic antidepressants may enhanced concomitant administration triprolidine\n",
      "effect: Furosemide probably loop diuretics given concomitantly metolazone\n",
      "effect: loop diuretics given concomitantly metolazone\n",
      "advise: MYKROX Tablets used antihypertensive drugs\n",
      "effect: Diuretic-induced hypokalemia increase sensitivity myocardium digitalis\n",
      "effect: Diuretic-induced hypokalemia may enhance neuromuscular blocking effects curariform drugs\n",
      "effect: Diuretic-induced hypokalemia may enhance neuromuscular blocking effects curariform drugs ( tubocurarine\n",
      "effect: Salicylates Other Non-Steroidal Anti-Inflammatory Drugs : May decrease antihypertensive effects MYKROX\n",
      "effect: Non-Steroidal Anti-Inflammatory Drugs : May decrease antihypertensive effects MYKROX\n",
      "effect: Metolazone may decrease arterial responsiveness norepinephrine\n",
      "effect: Methenamine : Efficacy may decreased due urinary alkalizing effect metolazone\n",
      "effect: Metolazone , well thiazide-like diuretics , may affect hypoprothrombinemic response anticoagulants\n",
      "effect: morphine potentiated presence CNS depressants\n",
      "effect: morphine potentiated presence CNS depressants alcohol\n",
      "effect: morphine potentiated presence CNS depressants alcohol , sedatives\n",
      "effect: morphine potentiated presence CNS depressants alcohol , sedatives , antihistaminics\n",
      "effect: morphine potentiated presence CNS depressants alcohol , sedatives , antihistaminics , psychotropic drugs\n",
      "effect: neuroleptics conjunction oral morphine\n",
      "advise: Agonist/antagonist analgesics ( i.e. , pentazocine , nalbuphine , butorphanol , buprenorphine ) NOT administered patients received receiving course therapy proof opioid agonist analgesic\n",
      "advise: pentazocine , nalbuphine , butorphanol , buprenorphine ) NOT administered patients received receiving course therapy proof opioid agonist analgesic\n",
      "advise: nalbuphine , butorphanol , buprenorphine ) NOT administered patients received receiving course therapy proof opioid agonist analgesic\n",
      "advise: butorphanol , buprenorphine ) NOT administered patients received receiving course therapy proof opioid agonist analgesic\n",
      "advise: buprenorphine ) NOT administered patients received receiving course therapy proof opioid agonist analgesic\n",
      "mechanism: ascorbic acid may influence intensity duration action bishydroxycoumarin\n",
      "effect: potassium-sparing diuretics ( spironolactone , triamterene , amiloride ) potassium supplements concomitantly ACE inhibitors\n",
      "effect: spironolactone , triamterene , amiloride ) potassium supplements concomitantly ACE inhibitors\n",
      "effect: triamterene , amiloride ) potassium supplements concomitantly ACE inhibitors\n",
      "effect: amiloride ) potassium supplements concomitantly ACE inhibitors\n",
      "effect: potassium supplements concomitantly ACE inhibitors\n",
      "effect: ACE inhibitors therapy lithium\n",
      "effect: diuretic also used , risk lithium\n",
      "int: alcohol phentermine hydrochloride\n",
      "mechanism: cholestyramine administration decreased mean AUC total ezetimibe\n",
      "effect: ezetimibe cholestyramine\n",
      "advise: ZETIA fibrates\n",
      "mechanism: fenofibrate administration increased total ezetimibe\n",
      "mechanism: ezetimibe level increased 12-fold one renal transplant patient receiving multiple medications , including cyclosporine\n",
      "advise: ezetimibe cyclosporine\n",
      "effect: reserpine ) may additive effect given beta-blocking agents\n",
      "effect: Vasopressors , particularly metaraminol , may cause serious cardiac arrhythmias halothane\n",
      "effect: metaraminol , may cause serious cardiac arrhythmias halothane\n",
      "effect: sympathomimetic pressor amines markedly potentiated patients receiving monoamine oxidase inhibitors\n",
      "effect: sympathomimetic pressor amines markedly potentiated patients receiving monoamine oxidase inhibitors ( MAOI\n",
      "effect: adrenergic agents may also potentiated tricyclic antidepressants\n",
      "mechanism: Trimethoprim may inhibit hepatic metabolism phenytoin\n",
      "mechanism: Trimethoprim , given common clinical dosage , increased phenytoin\n",
      "mechanism: Trimethoprim , given common clinical dosage , increased phenytoin half-life 51 % decreased phenytoin\n",
      "effect: diuretics , especially started recently , may occasionally experience excessive reduction blood pressure initiation ACEON\n",
      "effect: diuretic increasing salt intake prior initiation treatment perindopril\n",
      "advise: diuretics interrupted , close medical supervision provided first dose ACEON\n",
      "mechanism: digoxin plasma concentration\n",
      "mechanism: digoxin plasma concentration perindopril/perindoprilat\n",
      "int: perindopril gentamicin\n",
      "effect: Anticoagulants ( heparin vitamin K antagonists ) drugs alter platelet function ( acetylsalicylic acid , dipyridamole , GP IIb/IIIa inhibitors ) may increase risk bleeding administered prior , , TNKase\n",
      "effect: heparin vitamin K antagonists ) drugs alter platelet function ( acetylsalicylic acid , dipyridamole , GP IIb/IIIa inhibitors ) may increase risk bleeding administered prior , , TNKase\n",
      "effect: vitamin K antagonists ) drugs alter platelet function ( acetylsalicylic acid , dipyridamole , GP IIb/IIIa inhibitors ) may increase risk bleeding administered prior , , TNKase\n",
      "effect: acetylsalicylic acid , dipyridamole , GP IIb/IIIa inhibitors ) may increase risk bleeding administered prior , , TNKase\n",
      "effect: dipyridamole , GP IIb/IIIa inhibitors ) may increase risk bleeding administered prior , , TNKase\n",
      "mechanism: ketoconazole 200 mg twice daily increased retapamulin geometric mean AUC ( 0-24 ) Cmax 81 % topical application retapamulin\n",
      "effect: propoxyphene additive CNS depressants\n",
      "effect: propoxyphene additive CNS depressants , including alcohol\n",
      "mechanism: cyclosporin methylprednisolone\n",
      "effect: methylprednisolone cyclosporin\n",
      "mechanism: phenobarbital , phenytoin , rifampin may increase clearance methylprednisolone\n",
      "advise: phenobarbital , phenytoin , rifampin may increase clearance methylprednisolone may require increased methylprednisolone\n",
      "mechanism: phenytoin , rifampin may increase clearance methylprednisolone\n",
      "advise: phenytoin , rifampin may increase clearance methylprednisolone may require increased methylprednisolone\n",
      "mechanism: rifampin may increase clearance methylprednisolone\n",
      "advise: rifampin may increase clearance methylprednisolone may require increased methylprednisolone\n",
      "mechanism: troleandomycin ketoconazole may inhibit metabolism methylprednisolone\n",
      "mechanism: ketoconazole may inhibit metabolism methylprednisolone\n",
      "mechanism: Methylprednisolone may increase clearance chronic high dose aspirin\n",
      "effect: salicylate toxicity methylprednisolone\n",
      "advise: Aspirin used cautiously conjunction corticosteroids\n",
      "effect: anticoagulant given concurrently corticosteroids\n",
      "mechanism: Ketoconazole , inhibitor drug metabolizing enzyme CYP3A4 , significantly increased plasma concentrations tolterodine\n",
      "advise: ketoconazole potent CYP3A4 inhibitors azole antifungals ( eg , itraconazole , miconazole ) macrolide antibiotics ( eg , erythromycin , clarithromycin ) cyclosporine vinblastine , recommended dose DETROL LA\n",
      "advise: azole antifungals ( eg , itraconazole , miconazole ) macrolide antibiotics ( eg , erythromycin , clarithromycin ) cyclosporine vinblastine , recommended dose DETROL LA\n",
      "advise: itraconazole , miconazole ) macrolide antibiotics ( eg , erythromycin , clarithromycin ) cyclosporine vinblastine , recommended dose DETROL LA\n",
      "advise: miconazole ) macrolide antibiotics ( eg , erythromycin , clarithromycin ) cyclosporine vinblastine , recommended dose DETROL LA\n",
      "advise: macrolide antibiotics ( eg , erythromycin , clarithromycin ) cyclosporine vinblastine , recommended dose DETROL LA\n",
      "advise: erythromycin , clarithromycin ) cyclosporine vinblastine , recommended dose DETROL LA\n",
      "advise: clarithromycin ) cyclosporine vinblastine , recommended dose DETROL LA\n",
      "advise: cyclosporine vinblastine , recommended dose DETROL LA\n",
      "advise: vinblastine , recommended dose DETROL LA\n",
      "mechanism: ketoconazole , potent inhibitor cytochrome P450 3A4 , may increase plasma levels mometasone furoate\n",
      "effect: anticholinergic drugs : amantadine\n",
      "effect: anticholinergic drugs : amantadine , antiarrhythmic agents class I\n",
      "effect: anticholinergic drugs : amantadine , antiarrhythmic agents class I ( e.g. , quinidine\n",
      "effect: anticholinergic drugs : amantadine , antiarrhythmic agents class I ( e.g. , quinidine ) , antihistamines\n",
      "effect: anticholinergic drugs : amantadine , antiarrhythmic agents class I ( e.g. , quinidine ) , antihistamines , antipsychotic agents\n",
      "effect: anticholinergic drugs : amantadine , antiarrhythmic agents class I ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines\n",
      "effect: anticholinergic drugs : amantadine , antiarrhythmic agents class I ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines\n",
      "effect: anticholinergic drugs : amantadine , antiarrhythmic agents class I ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors\n",
      "effect: anticholinergic drugs : amantadine , antiarrhythmic agents class I ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , narcotic analgesics\n",
      "effect: anticholinergic drugs : amantadine , antiarrhythmic agents class I ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , narcotic analgesics ( e.g. , meperidine\n",
      "effect: anticholinergic drugs : amantadine , antiarrhythmic agents class I ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates\n",
      "effect: anticholinergic drugs : amantadine , antiarrhythmic agents class I ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates nitrites\n",
      "effect: anticholinergic drugs : amantadine , antiarrhythmic agents class I ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates nitrites , sympathomimetic agents\n",
      "effect: anticholinergic drugs : amantadine , antiarrhythmic agents class I ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates nitrites , sympathomimetic agents , tricyclic antidepressants\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "effect: Anticholinergics antagonize effects antiglaucoma agents\n",
      "effect: Anticholinergic drugs presence increased intraocular pressure may hazardous taken concurrently agents corticosteroids\n",
      "mechanism: Anticholinergic agents may affect gastrointestinal absorption various drugs , slowly dissolving dosage forms digoxin\n",
      "effect: Anticholinergic drugs may antagonize effects drugs alter gastrointestinal motility , metoclopramide\n",
      "mechanism: antacids may interfere absorption anticholinergic agents\n",
      "int: Trilostane may interact aminoglutethimide\n",
      "int: Trilostane may interact aminoglutethimide mitotane\n",
      "advise: Matulane exhibits monoamine oxidase inhibitory activity , sympathomimetic drugs\n",
      "advise: Matulane exhibits monoamine oxidase inhibitory activity , sympathomimetic drugs , tricyclic antidepressant\n",
      "advise: Matulane exhibits monoamine oxidase inhibitory activity , sympathomimetic drugs , tricyclic antidepressant drugs ( e.g. , amitriptyline HCl\n",
      "advise: Matulane exhibits monoamine oxidase inhibitory activity , sympathomimetic drugs , tricyclic antidepressant drugs ( e.g. , amitriptyline HCl , imipramine HCl\n",
      "advise: Matulane exhibits monoamine oxidase inhibitory activity , sympathomimetic drugs , tricyclic antidepressant drugs ( e.g. , amitriptyline HCl , imipramine HCl ) drugs foods known high tyramine\n",
      "advise: tetracyclines shown depress plasma prothrombin activity , patients anticoagulant\n",
      "advise: tetracycline class drugs conjunction penicillin\n",
      "mechanism: tetracyclines impaired antacids containing aluminum\n",
      "mechanism: tetracyclines impaired antacids containing aluminum , calcium\n",
      "mechanism: tetracyclines impaired antacids containing aluminum , calcium magnesium\n",
      "mechanism: tetracyclines impaired antacids containing aluminum , calcium magnesium ,\n",
      "effect: tetracycline methoxyflurane\n",
      "effect: tetracyclines oral contraceptives\n",
      "advise: Pilocarpine administered caution patients taking beta adrenergic antagonists\n",
      "effect: PURINETHOL ( mercaptopurine ) TABLOID\n",
      "effect: PURINETHOL ( mercaptopurine ) TABLOID brand Thioguanine\n",
      "effect: mercaptopurine ) TABLOID\n",
      "effect: mercaptopurine ) TABLOID brand Thioguanine\n",
      "mechanism: aminosalicylate derivatives ( e.g. , olsalazine , mesalazine , sulphasalazine ) inhibit TPMT enzyme , administered caution patients receiving concurrent thioguanine\n",
      "mechanism: olsalazine , mesalazine , sulphasalazine ) inhibit TPMT enzyme , administered caution patients receiving concurrent thioguanine\n",
      "mechanism: mesalazine , sulphasalazine ) inhibit TPMT enzyme , administered caution patients receiving concurrent thioguanine\n",
      "mechanism: sulphasalazine ) inhibit TPMT enzyme , administered caution patients receiving concurrent thioguanine\n",
      "advise: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS\n",
      "advise: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS\n",
      "advise: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES\n",
      "advise: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS\n",
      "advise: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS\n",
      "advise: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS ( INCLUDING BARBITURATES\n",
      "advise: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS ( INCLUDING BARBITURATES ) , TRICYCLIC ANTIDEPRESSANTS\n",
      "advise: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS ( INCLUDING BARBITURATES ) , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS\n",
      "advise: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS ( INCLUDING BARBITURATES ) , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS ( INCLUDING ALCOHOL\n",
      "effect: testolactone may increase effects oral anticoagulants\n",
      "mechanism: Posicor inhibits liver 's ability metabolize drugs - terfenadine\n",
      "mechanism: Posicor inhibits liver 's ability metabolize drugs - terfenadine , astemizole\n",
      "mechanism: Posicor inhibits liver 's ability metabolize drugs - terfenadine , astemizole , cisapride\n",
      "mechanism: Posicor inhibits liver 's ability metabolize drugs - terfenadine , astemizole , cisapride , cyclosporine\n",
      "mechanism: Posicor inhibits liver 's ability metabolize drugs - terfenadine , astemizole , cisapride , cyclosporine , tricyclic antidepressants\n",
      "mechanism: cimetidine inhibits mebendazole\n",
      "advise: antibiotics sulfonamides generally treated ganglion blockers\n",
      "advise: sulfonamides generally treated ganglion blockers\n",
      "effect: Mecamylamine may potentiated anesthesia , antihypertensive drugs\n",
      "effect: Mecamylamine may potentiated anesthesia , antihypertensive drugs alcohol\n",
      "effect: Sulfoxone may increase effects barbiturates\n",
      "effect: Sulfoxone may increase effects barbiturates , tolbutamide\n",
      "effect: Sulfoxone may increase effects barbiturates , tolbutamide , uricosurics\n",
      "effect: anticoagulants may potentiated anti-vitamin-K activity attributed methimazole\n",
      "advise: midazolam administered concomitantly drugs known inhibit cytochrome P450 3A4 enzyme system ( ie , drugs drug classes azole antimycotics\n",
      "advise: midazolam administered concomitantly drugs known inhibit cytochrome P450 3A4 enzyme system ( ie , drugs drug classes azole antimycotics , protease inhibitors\n",
      "advise: midazolam administered concomitantly drugs known inhibit cytochrome P450 3A4 enzyme system ( ie , drugs drug classes azole antimycotics , protease inhibitors , calcium channel antagonists\n",
      "advise: midazolam administered concomitantly drugs known inhibit cytochrome P450 3A4 enzyme system ( ie , drugs drug classes azole antimycotics , protease inhibitors , calcium channel antagonists , macrolide antibiotics\n",
      "mechanism: erythromycin , diltiazem , verapamil , ketoconazole , fluconazole itraconazole shown significantly increase C max AUC orally administered midazolam\n",
      "mechanism: diltiazem , verapamil , ketoconazole , fluconazole itraconazole shown significantly increase C max AUC orally administered midazolam\n",
      "mechanism: verapamil , ketoconazole , fluconazole itraconazole shown significantly increase C max AUC orally administered midazolam\n",
      "mechanism: ketoconazole , fluconazole itraconazole shown significantly increase C max AUC orally administered midazolam\n",
      "mechanism: fluconazole itraconazole shown significantly increase C max AUC orally administered midazolam\n",
      "mechanism: itraconazole shown significantly increase C max AUC orally administered midazolam\n",
      "mechanism: ritonavir nelfinavir may cause intense prolonged sedation respiratory depression due decrease plasma clearance midazolam\n",
      "mechanism: nelfinavir may cause intense prolonged sedation respiratory depression due decrease plasma clearance midazolam\n",
      "mechanism: rifampin , carbamazepine , phenytoin , induce metabolism caused markedly decreased C max AUC oral midazolam\n",
      "mechanism: carbamazepine , phenytoin , induce metabolism caused markedly decreased C max AUC oral midazolam\n",
      "mechanism: phenytoin , induce metabolism caused markedly decreased C max AUC oral midazolam\n",
      "effect: VERSED Syrup accentuated concomitantly administered medication depresses central nervous system , particularly narcotics\n",
      "effect: VERSED Syrup accentuated concomitantly administered medication depresses central nervous system , particularly narcotics ( eg , morphine\n",
      "effect: VERSED Syrup accentuated concomitantly administered medication depresses central nervous system , particularly narcotics ( eg , morphine , meperidine\n",
      "effect: VERSED Syrup accentuated concomitantly administered medication depresses central nervous system , particularly narcotics ( eg , morphine , meperidine fentanyl\n",
      "effect: VERSED Syrup accentuated concomitantly administered medication depresses central nervous system , particularly narcotics ( eg , morphine , meperidine fentanyl ) , propofol\n",
      "effect: VERSED Syrup accentuated concomitantly administered medication depresses central nervous system , particularly narcotics ( eg , morphine , meperidine fentanyl ) , propofol , ketamine\n",
      "effect: VERSED Syrup accentuated concomitantly administered medication depresses central nervous system , particularly narcotics ( eg , morphine , meperidine fentanyl ) , propofol , ketamine , nitrous oxide\n",
      "effect: VERSED Syrup accentuated concomitantly administered medication depresses central nervous system , particularly narcotics ( eg , morphine , meperidine fentanyl ) , propofol , ketamine , nitrous oxide , secobarbital\n",
      "effect: VERSED Syrup accentuated concomitantly administered medication depresses central nervous system , particularly narcotics ( eg , morphine , meperidine fentanyl ) , propofol , ketamine , nitrous oxide , secobarbital droperidol\n",
      "mechanism: SUTENT strong inhibitors CYP3A4 family ( e.g. , ketoconazole\n",
      "mechanism: SUTENT strong inhibitors CYP3A4 family ( e.g. , ketoconazole , itraconazole\n",
      "mechanism: SUTENT strong inhibitors CYP3A4 family ( e.g. , ketoconazole , itraconazole , clarithromycin\n",
      "mechanism: SUTENT strong inhibitors CYP3A4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir\n",
      "mechanism: SUTENT strong inhibitors CYP3A4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir\n",
      "mechanism: SUTENT strong inhibitors CYP3A4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone\n",
      "mechanism: SUTENT strong inhibitors CYP3A4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir\n",
      "mechanism: SUTENT strong inhibitors CYP3A4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir\n",
      "mechanism: SUTENT strong inhibitors CYP3A4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir\n",
      "mechanism: SUTENT strong inhibitors CYP3A4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin\n",
      "mechanism: SUTENT strong inhibitors CYP3A4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole\n",
      "mechanism: SUTENT inducers CYP3A4 family ( e.g. , dexamethasone\n",
      "mechanism: SUTENT inducers CYP3A4 family ( e.g. , dexamethasone , phenytoin\n",
      "mechanism: SUTENT inducers CYP3A4 family ( e.g. , dexamethasone , phenytoin , carbamazepine\n",
      "mechanism: SUTENT inducers CYP3A4 family ( e.g. , dexamethasone , phenytoin , carbamazepine , rifampin\n",
      "mechanism: SUTENT inducers CYP3A4 family ( e.g. , dexamethasone , phenytoin , carbamazepine , rifampin , rifabutin\n",
      "mechanism: SUTENT inducers CYP3A4 family ( e.g. , dexamethasone , phenytoin , carbamazepine , rifampin , rifabutin , rifapentin\n",
      "mechanism: SUTENT inducers CYP3A4 family ( e.g. , dexamethasone , phenytoin , carbamazepine , rifampin , rifabutin , rifapentin , phenobarbital\n",
      "effect: methyldopa used antihypertensive drugs\n",
      "advise: anesthetics methyldopa\n",
      "advise: methyldopa lithium\n",
      "mechanism: methyldopa ingested ferrous sulfate\n",
      "mechanism: methyldopa ingested ferrous sulfate ferrous gluconate\n",
      "advise: methyldopa ferrous sulfate\n",
      "advise: methyldopa ferrous sulfate ferrous gluconate\n",
      "effect: ketoconazole recommended doses terfenadine\n",
      "mechanism: ketoconazole markedly inhibits metabolism terfenadine\n",
      "advise: ketoconazole terfenadine\n",
      "mechanism: terfenadine itraconazole\n",
      "advise: itraconazole terfenadine\n",
      "advise: azole-type antifungal agents ( including fluconazole , metronidazole , miconazole ) ketoconazole , itraconazole , concomitant use products terfenadine\n",
      "advise: fluconazole , metronidazole , miconazole ) ketoconazole , itraconazole , concomitant use products terfenadine\n",
      "advise: metronidazole , miconazole ) ketoconazole , itraconazole , concomitant use products terfenadine\n",
      "advise: miconazole ) ketoconazole , itraconazole , concomitant use products terfenadine\n",
      "mechanism: erythromycin clarithromycin exert effect terfenadine\n",
      "mechanism: clarithromycin exert effect terfenadine\n",
      "advise: terfenadine clarithromycin\n",
      "advise: terfenadine clarithromycin , erythromycin\n",
      "advise: terfenadine clarithromycin , erythromycin , troleandomycin\n",
      "advise: terfenadine macrolide antibiotics\n",
      "advise: terfenadine macrolide antibiotics , including azithromycin\n",
      "effect: minoxidil cause orthostatic hypotension , administration patients already receiving guanethidine\n",
      "advise: guanethidine discontinued well minoxidil\n",
      "advise: beta adrenergic aerosol bronchodilators used concomitantly Alupent\n",
      "advise: beta adrenergic aerosol bronchodilators used concomitantly Alupent ( metaproterenol sulfate\n",
      "advise: Beta adrenergic agonists administered caution patients treated monoamine oxidase inhibitors\n",
      "advise: Beta adrenergic agonists administered caution patients treated monoamine oxidase inhibitors tricyclic antidepressants\n",
      "int: macrolides interact terfenadine\n",
      "int: macrolides interact terfenadine astemizole\n",
      "advise: roxithromycin terfenadine\n",
      "advise: roxithromycin terfenadine astemizole\n",
      "mechanism: pimozide : Other drugs cisapride pimozide , metabolised hepatic CYP3A isozymes associated QT interval prolongation and/or cardiac arrythmias ( typically torsades de pointe ) result increase serum level subsequent interaction significant inhibitors isozyme , including macrolide antibacterials\n",
      "mechanism: cisapride pimozide , metabolised hepatic CYP3A isozymes associated QT interval prolongation and/or cardiac arrythmias ( typically torsades de pointe ) result increase serum level subsequent interaction significant inhibitors isozyme , including macrolide antibacterials\n",
      "mechanism: vigabatrin causes statistically significant increase plasma clearance carbamazepine\n",
      "mechanism: vigabatrin phenytoin\n",
      "mechanism: SKELID decreased 80 % calcium\n",
      "mechanism: aluminum- magnesium-containing antacids , administered 1 hour SKELID\n",
      "mechanism: magnesium-containing antacids , administered 1 hour SKELID\n",
      "mechanism: Aspirin may decrease bioavailability SKELID\n",
      "mechanism: SKELID increased 2-4 fold indomethacin\n",
      "effect: Phenothiazines capable potentiating CNS depressants\n",
      "effect: Phenothiazines capable potentiating CNS depressants ( e.g. , barbiturates\n",
      "effect: Phenothiazines capable potentiating CNS depressants ( e.g. , barbiturates , anesthetics\n",
      "effect: Phenothiazines capable potentiating CNS depressants ( e.g. , barbiturates , anesthetics , opiates\n",
      "effect: Phenothiazines capable potentiating CNS depressants ( e.g. , barbiturates , anesthetics , opiates , alcohol\n",
      "mechanism: ketoconazole approximately doubled paricalcitol\n",
      "advise: paricalcitol ketoconazole\n",
      "advise: paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir\n",
      "advise: paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir , clarithromycin\n",
      "advise: paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir\n",
      "advise: paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole\n",
      "advise: paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone\n",
      "advise: paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir\n",
      "advise: paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir\n",
      "advise: paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir\n",
      "advise: paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin\n",
      "advise: paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin voriconazole\n",
      "advise: Zemplar Capsules may required , iPTH serum calcium concentrations closely monitored patient initiates discontinues therapy strong CYP3A4 inhibitor ketoconazole\n",
      "mechanism: fat-soluble vitamins , cholestyramine\n",
      "mechanism: cholestyramine , may interfere absorption Zemplar\n",
      "effect: Methysergide may reverse analgesic activity narcotic analgesics\n",
      "mechanism: 5-FU plasma concentrations approximately 20 % observed doses 130 mg/m2 ELOXATIN\n",
      "int: Methscopolamine may interact antidepressants ( tricyclic\n",
      "int: Methscopolamine may interact antidepressants ( tricyclic type ) , MAO inhibitors\n",
      "int: Methscopolamine may interact antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine\n",
      "int: Methscopolamine may interact antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid\n",
      "int: Methscopolamine may interact antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine\n",
      "int: Methscopolamine may interact antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid\n",
      "int: Methscopolamine may interact antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline\n",
      "int: Methscopolamine may interact antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone\n",
      "int: Methscopolamine may interact antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine\n",
      "int: Methscopolamine may interact antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine\n",
      "int: Methscopolamine may interact antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines\n",
      "int: Methscopolamine may interact antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine\n",
      "int: Methscopolamine may interact antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , anticholinergics\n",
      "int: Methscopolamine may interact antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , anticholinergics , potassium chloride\n",
      "int: Methscopolamine may interact antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , anticholinergics , potassium chloride supplements , antacids\n",
      "int: Methscopolamine may interact antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines\n",
      "int: Methscopolamine may interact antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines ( e.g. ,\n",
      "int: Methscopolamine may interact antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines ( e.g. , kaolin-pectin\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "int: Methscopolamine may interact antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines ( e.g. , kaolin-pectin ) , phenothiazines\n",
      "int: Methscopolamine may interact antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines ( e.g. , kaolin-pectin ) , phenothiazines ( e.g. , chlorpromazine\n",
      "int: Methscopolamine may interact antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines ( e.g. , kaolin-pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine\n",
      "effect: Leukine , lithium\n",
      "effect: Leukine , lithium corticosteroids\n",
      "mechanism: Ethanol decreases elimination abacavir\n",
      "mechanism: methadone-maintenance therapy ( 40 mg 90 mg daily ) 600 mg ZIAGEN\n",
      "effect: trimetrexate AIDS patients indications could elicit activity include erythromycin\n",
      "effect: trimetrexate AIDS patients indications could elicit activity include erythromycin , rifampin\n",
      "effect: trimetrexate AIDS patients indications could elicit activity include erythromycin , rifampin , rifabutin\n",
      "effect: trimetrexate AIDS patients indications could elicit activity include erythromycin , rifampin , rifabutin , ketoconazole\n",
      "effect: trimetrexate AIDS patients indications could elicit activity include erythromycin , rifampin , rifabutin , ketoconazole , fluconazole\n",
      "mechanism: cimetidine caused significant reduction trimetrexate\n",
      "mechanism: imidazole drugs ( clotrimazole , ketoconazole , miconazole ) potent , non-competitive inhibitors trimetrexate\n",
      "mechanism: clotrimazole , ketoconazole , miconazole ) potent , non-competitive inhibitors trimetrexate\n",
      "mechanism: ketoconazole , miconazole ) potent , non-competitive inhibitors trimetrexate\n",
      "mechanism: miconazole ) potent , non-competitive inhibitors trimetrexate\n",
      "effect: acetylcholine chloride ( Miochol ) carbachol ( Carboptic , Isopto Carbachol ) may decrease effects suprofen\n",
      "effect: Miochol ) carbachol ( Carboptic , Isopto Carbachol ) may decrease effects suprofen\n",
      "effect: carbachol ( Carboptic , Isopto Carbachol ) may decrease effects suprofen\n",
      "effect: Carboptic , Isopto Carbachol ) may decrease effects suprofen\n",
      "effect: Isopto Carbachol ) may decrease effects suprofen\n",
      "effect: Nalidixic acid together high-dose intravenous melphalan\n",
      "effect: melphalan subsequently received cyclosporin\n",
      "int: norepinephrine dobutamine incompatible sodium bicarbonate\n",
      "int: dobutamine incompatible sodium bicarbonate\n",
      "effect: oxybutynin anticholinergic drugs\n",
      "mechanism: DITROPAN XL administered ketoconazole\n",
      "mechanism: antimycotic agents ( e.g. , itraconazole miconazole ) macrolide antibiotics ( e.g. , erythromycin clarithromycin ) , may alter oxybutynin\n",
      "mechanism: itraconazole miconazole ) macrolide antibiotics ( e.g. , erythromycin clarithromycin ) , may alter oxybutynin\n",
      "mechanism: miconazole ) macrolide antibiotics ( e.g. , erythromycin clarithromycin ) , may alter oxybutynin\n",
      "mechanism: macrolide antibiotics ( e.g. , erythromycin clarithromycin ) , may alter oxybutynin\n",
      "mechanism: erythromycin clarithromycin ) , may alter oxybutynin\n",
      "mechanism: clarithromycin ) , may alter oxybutynin\n",
      "mechanism: Sirolimus AUC increased 21 % effect Cmax presence steady-state MYCAMINE\n",
      "mechanism: Nifedipine AUC Cmax increased 18 % 42 % , respectively , presence steady-state MYCAMINE\n",
      "advise: sirolimus nifedipine combination MYCAMINE\n",
      "advise: nifedipine combination MYCAMINE\n",
      "effect: diphosphonate use appears reduce anti-resorptive response Calcitonin ( salmon )\n",
      "effect: bacteriostatic antibiotics ( e.g. , erythromycin , tetracycline ) may diminish bactericidal effects penicillins\n",
      "effect: erythromycin , tetracycline ) may diminish bactericidal effects penicillins\n",
      "effect: tetracycline ) may diminish bactericidal effects penicillins\n",
      "mechanism: Penicillin blood levels may prolonged concurrent administration probenecid\n",
      "advise: SPIRIVA anticholinergic\n",
      "advise: SPIRIVA anticholinergic containing drugs ( e.g. , ipratropium\n",
      "advise: Dopamine antagonists , neuroleptics ( phenothiazines , butyrophenones , thioxanthines ) metoclopramide , ordinarily administered concurrently Permax\n",
      "advise: neuroleptics ( phenothiazines , butyrophenones , thioxanthines ) metoclopramide , ordinarily administered concurrently Permax\n",
      "advise: phenothiazines , butyrophenones , thioxanthines ) metoclopramide , ordinarily administered concurrently Permax\n",
      "advise: butyrophenones , thioxanthines ) metoclopramide , ordinarily administered concurrently Permax\n",
      "advise: thioxanthines ) metoclopramide , ordinarily administered concurrently Permax\n",
      "advise: metoclopramide , ordinarily administered concurrently Permax\n",
      "mechanism: Terbinafine decreases clearance caffeine\n",
      "mechanism: Terbinafine increases clearance cyclosporine\n",
      "effect: terbinafine warfarin\n",
      "mechanism: Terbinafine clearance increased 100 % rifampin\n",
      "mechanism: Terbinafine clearance increased 100 % rifampin , CyP450 enzyme inducer , decreased 33 % cimetidine\n",
      "advise: alcohol used caution patients currently receiving pentazocine\n",
      "advise: phenobarbital rifampin , co-administered montelukast\n",
      "advise: rifampin , co-administered montelukast\n",
      "advise: phenobarbital rifampin , co-administered montelukast\n",
      "advise: rifampin , co-administered montelukast\n",
      "mechanism: Mitotane reported accelerate metabolism warfarin\n",
      "advise: Mitotane patients coumarin-type anticoagulants\n",
      "mechanism: contraceptives shown significant increase plasma vitamin A\n",
      "effect: DIFLUCAN oral hypoglycemic agents\n",
      "effect: DIFLUCAN glyburide\n",
      "mechanism: DIFLUCAN reduces metabolism tolbutamide\n",
      "mechanism: DIFLUCAN reduces metabolism tolbutamide , glyburide\n",
      "mechanism: DIFLUCAN reduces metabolism tolbutamide , glyburide , glipizide\n",
      "advise: DIFLUCAN used concomitantly sulfonylurea oral hypoglycemic agents\n",
      "effect: DIFLUCAN coumarin-type anticoagulants\n",
      "effect: fluconazole concurrently warfarin\n",
      "advise: DIFLUCAN coumarin-type anticoagulants\n",
      "mechanism: DIFLUCAN increases plasma concentrations phenytoin\n",
      "advise: DIFLUCAN phenytoin\n",
      "mechanism: DIFLUCAN may significantly increase cyclosporine\n",
      "advise: DIFLUCAN cyclosporine\n",
      "mechanism: Rifampin enhances metabolism concurrently administered DIFLUCAN\n",
      "advise: DIFLUCAN administered rifampin\n",
      "mechanism: DIFLUCAN increases serum concentrations theophylline\n",
      "advise: DIFLUCAN theophylline\n",
      "effect: azole antifungals conjunction terfenadine\n",
      "mechanism: DIFLUCAN taken doses 400 mg per day greater significantly increases plasma levels terfenadine\n",
      "advise: fluconazole doses 400 mg greater terfenadine\n",
      "advise: fluconazole doses lower 400 mg/day terfenadine\n",
      "effect: fluconazole cisapride\n",
      "mechanism: fluconazole 200 mg daily cisapride\n",
      "advise: fluconazole cisapride\n",
      "mechanism: fluconazole patients concurrently taking astemizole\n",
      "effect: fluconazole rifabutin\n",
      "advise: rifabutin fluconazole\n",
      "effect: fluconazole tacrolimus\n",
      "advise: tacrolimus fluconazole\n",
      "mechanism: midazolam , fluconazole\n",
      "effect: midazolam appears pronounced following oral administration fluconazole\n",
      "advise: short-acting benzodiazepines , metabolized cytochrome P450 system , concomitantly administered fluconazole\n",
      "mechanism: Fluconazole tablets coadministered ethinyl\n",
      "mechanism: Fluconazole tablets coadministered ethinyl estradiol-\n",
      "mechanism: fluconazole inhibit metabolism ethinyl estradiol\n",
      "mechanism: fluconazole inhibit metabolism ethinyl estradiol levonorgestrel\n",
      "mechanism: phenytoin , carbamazepine , rifampicin ) , clearance ondansetron\n",
      "mechanism: phenytoin , carbamazepine , rifampicin ) , clearance ondansetron significantly increased ondansetron\n",
      "mechanism: carbamazepine , rifampicin ) , clearance ondansetron\n",
      "mechanism: carbamazepine , rifampicin ) , clearance ondansetron significantly increased ondansetron\n",
      "mechanism: rifampicin ) , clearance ondansetron\n",
      "mechanism: rifampicin ) , clearance ondansetron significantly increased ondansetron\n",
      "effect: ondansetron may associated increase patient controlled administration\n",
      "effect: procaine hydrochloride anticholinesterase agents\n",
      "mechanism: anticholinesterases inhibit breakdown procaine hydrochloride\n",
      "effect: procaine hydrochloride CNS depressant medications\n",
      "mechanism: Hyaluronidase may increase diffusion rate procaine hydrochloride\n",
      "effect: procaine hydrochloride neuromuscular blocking agents\n",
      "effect: procaine hydrochloride sulfonamides\n",
      "mechanism: acetazolamide procaine hydrochloride\n",
      "effect: TRENTAL without anticoagulants\n",
      "effect: TRENTAL without anticoagulants platelet aggregation inhibitors\n",
      "mechanism: TRENTAL\n",
      "effect: sulfamethoxazole may prolong prothrombin time patients receiving anticoagulant warfarin\n",
      "mechanism: Sulfamethoxazole may inhibit hepatic metabolism phenytoin\n",
      "mechanism: sulfamethoxazole produced slight significant increase half-life phenytoin\n",
      "mechanism: Sulfonamides also displace methotrexate\n",
      "effect: Zidovudine competitively inhibits intracellular phosphorylation stavudine\n",
      "advise: zidovudine combination ZERIT\n",
      "effect: stavudine also inhibited relevant concentrations doxorubicin\n",
      "effect: stavudine also inhibited relevant concentrations doxorubicin ribavirin\n",
      "mechanism: Probenecid competes meropenem\n",
      "advise: probenecid meropenem\n",
      "mechanism: meropenem may reduce serum levels valproic acid\n",
      "advise: VESIcare administered therapeutic doses ketoconazole\n",
      "advise: aspirin methazolamide\n",
      "effect: aspirin carbonic anhydrase inhibitors\n",
      "mechanism: valproic acid decreases oral clearance temozolomide\n",
      "advise: ZEMURON administered following administration succinylcholine\n",
      "effect: Tetracycline , bacteriostatic antibiotic , may antagonize bactericidal effect penicillin\n",
      "effect: Thalidomide reported enhance sedative activity barbiturates\n",
      "effect: John 's Wort hormonal contraceptive agents\n",
      "mechanism: Myfortic decreased administered 12 stable renal transplant patients also taking\n",
      "mechanism: Myfortic decreased administered 12 stable renal transplant patients also taking magnesium-aluminum\n",
      "advise: Myfortic antacids\n",
      "advise: Myfortic administered concomitantly azathioprine\n",
      "advise: Myfortic administered concomitantly azathioprine mycophenolate mofetil\n",
      "advise: Myfortic cholestyramine\n",
      "advise: Myfortic cholestyramine agents may interfere enterohepatic recirculation drugs may bind bile acids , example bile acid sequestrates oral activated charcoal\n",
      "mechanism: levonorgesterol AUC decreased 15 % coadministered mycophenolate mofetil\n",
      "advise: contraceptives co- administered Myfortic\n",
      "advise: Myfortic , use live attenuated vaccines\n",
      "mechanism: ketoconazole , itraconazole , erythromycin , grapefruit juice may inhibit metabolism ( increasing serum levels mifepristone\n",
      "mechanism: itraconazole , erythromycin , grapefruit juice may inhibit metabolism ( increasing serum levels mifepristone\n",
      "mechanism: erythromycin , grapefruit juice may inhibit metabolism ( increasing serum levels mifepristone\n",
      "mechanism: anticonvulsants ( phenytoin , phenobarbital , carbamazepine ) may induce mifepristone\n",
      "mechanism: phenytoin , phenobarbital , carbamazepine ) may induce mifepristone\n",
      "mechanism: phenobarbital , carbamazepine ) may induce mifepristone\n",
      "mechanism: carbamazepine ) may induce mifepristone\n",
      "effect: Thiazide diuretics may accentuate orthostatic hypotension may occur phenothiazines\n",
      "effect: guanethidine related compounds may counteracted phenothiazines\n",
      "mechanism: propranolol phenothiazines\n",
      "effect: succinylcholine potentiate neuromuscular blocking effects nondepolarizing agents\n",
      "advise: succinylcholine observed administration MIVACRON\n",
      "int: nondepolarizing agents MIVACRON include certain antibiotics\n",
      "int: nondepolarizing agents MIVACRON include certain antibiotics ( e.g. , aminoglycosides\n",
      "int: nondepolarizing agents MIVACRON include certain antibiotics ( e.g. , aminoglycosides , tetracyclines\n",
      "int: nondepolarizing agents MIVACRON include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin\n",
      "int: nondepolarizing agents MIVACRON include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins\n",
      "int: nondepolarizing agents MIVACRON include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin\n",
      "int: nondepolarizing agents MIVACRON include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin\n",
      "int: nondepolarizing agents MIVACRON include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin\n",
      "int: nondepolarizing agents MIVACRON include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , sodium colistimethate\n",
      "int: nondepolarizing agents MIVACRON include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , sodium colistimethate ) , magnesium\n",
      "int: nondepolarizing agents MIVACRON include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , sodium colistimethate ) , magnesium salts , lithium\n",
      "int: nondepolarizing agents MIVACRON include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , sodium colistimethate ) , magnesium salts , lithium , local anesthetics\n",
      "int: nondepolarizing agents MIVACRON include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide\n",
      "int: nondepolarizing agents MIVACRON include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , quinidine\n",
      "int: MIVACRON include certain antibiotics\n",
      "int: MIVACRON include certain antibiotics ( e.g. , aminoglycosides\n",
      "int: MIVACRON include certain antibiotics ( e.g. , aminoglycosides , tetracyclines\n",
      "int: MIVACRON include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin\n",
      "int: MIVACRON include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins\n",
      "int: MIVACRON include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin\n",
      "int: MIVACRON include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin\n",
      "int: MIVACRON include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin\n",
      "int: MIVACRON include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , sodium colistimethate\n",
      "int: MIVACRON include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , sodium colistimethate ) , magnesium\n",
      "int: MIVACRON include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , sodium colistimethate ) , magnesium salts , lithium\n",
      "int: MIVACRON include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , sodium colistimethate ) , magnesium salts , lithium , local anesthetics\n",
      "int: MIVACRON include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide\n",
      "int: MIVACRON include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , quinidine\n",
      "effect: MIVACRON may enhanced drugs reduce plasma cholinesterase activity ( e.g. , chronically administered oral contraceptives\n",
      "effect: MIVACRON may enhanced drugs reduce plasma cholinesterase activity ( e.g. , chronically administered oral contraceptives , glucocorticoids\n",
      "effect: MIVACRON may enhanced drugs reduce plasma cholinesterase activity ( e.g. , chronically administered oral contraceptives , glucocorticoids , certain monoamine oxidase inhibitors\n",
      "effect: neuromuscular blocking agents demonstrated patients chronically administered phenytoin\n",
      "effect: neuromuscular blocking agents demonstrated patients chronically administered phenytoin carbamazepine\n",
      "effect: phenytoin carbamazepine therapy action MIVACRON\n",
      "effect: carbamazepine therapy action MIVACRON\n",
      "mechanism: tolbutamide , sodium salicylate sulfamethizole displaced protein-bound teniposide\n",
      "mechanism: sodium salicylate sulfamethizole displaced protein-bound teniposide\n",
      "mechanism: sulfamethizole displaced protein-bound teniposide\n",
      "mechanism: methotrexate observed vitro presence teniposide\n",
      "mechanism: Cholestyramine causes 60 % reduction absorption enterohepatic cycling raloxifene\n",
      "advise: Cholestyramine causes 60 % reduction absorption enterohepatic cycling raloxifene coadministered EVISTA\n",
      "advise: EVISTA given concurrently warfarin\n",
      "advise: EVISTA coadministered highly protein-bound drugs , clofibrate\n",
      "advise: EVISTA coadministered highly protein-bound drugs , clofibrate , indomethacin\n",
      "advise: EVISTA coadministered highly protein-bound drugs , clofibrate , indomethacin , naproxen\n",
      "advise: EVISTA coadministered highly protein-bound drugs , clofibrate , indomethacin , naproxen , ibuprofen\n",
      "advise: EVISTA coadministered highly protein-bound drugs , clofibrate , indomethacin , naproxen , ibuprofen , diazepam\n",
      "advise: EVISTA coadministered highly protein-bound drugs , clofibrate , indomethacin , naproxen , ibuprofen , diazepam , diazoxide\n",
      "int: anticonvulsants may interact Mephenytoin\n",
      "effect: Mephenytoin may also affect effects drugs , include steroid medications\n",
      "effect: Mephenytoin may also affect effects drugs , include steroid medications , warfarin\n",
      "effect: Mephenytoin may also affect effects drugs , include steroid medications , warfarin , certain heart medicines , birth control pills , anti-infective medicines\n",
      "effect: Mephenytoin may also affect effects drugs , include steroid medications , warfarin , certain heart medicines , birth control pills , anti-infective medicines , furosemide\n",
      "effect: Mephenytoin may also affect effects drugs , include steroid medications , warfarin , certain heart medicines , birth control pills , anti-infective medicines , furosemide theophylline\n",
      "int: Melatonin may interact following drugs : aspirin\n",
      "int: Melatonin may interact following drugs : aspirin NSAIDs\n",
      "int: Melatonin may interact following drugs : aspirin NSAIDs ( may lower melatonin levels ) , fluvoxamine\n",
      "int: Melatonin may interact following drugs : aspirin NSAIDs ( may lower melatonin levels ) , fluvoxamine ( bioavailability oral melatonin increased coadministration ) , beta blockers\n",
      "int: Melatonin may interact following drugs : aspirin NSAIDs ( may lower melatonin levels ) , fluvoxamine ( bioavailability oral melatonin increased coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine\n",
      "int: Melatonin may interact following drugs : aspirin NSAIDs ( may lower melatonin levels ) , fluvoxamine ( bioavailability oral melatonin increased coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports psychotic episodes coadministered ) , progestin\n",
      "int: Melatonin may interact following drugs : aspirin NSAIDs ( may lower melatonin levels ) , fluvoxamine ( bioavailability oral melatonin increased coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports psychotic episodes coadministered ) , progestin ( coadministration melatonin progestin inhibit ovarian function women ) , benzodiazepenes\n",
      "int: Melatonin may interact following drugs : aspirin NSAIDs ( may lower melatonin levels ) , fluvoxamine ( bioavailability oral melatonin increased coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports psychotic episodes coadministered ) , progestin ( coadministration melatonin progestin inhibit ovarian function women ) , benzodiazepenes sedating drugs ( may result additive sedation increased incidence adverse effects ) , corticosteroids\n",
      "effect: melatonin progestin\n",
      "effect: melatonin corticosteroids\n",
      "effect: proton pump inhibitors , including pantoprazole , warfarin\n",
      "effect: pantoprazole , warfarin\n",
      "advise: proton pump inhibitors warfarin\n",
      "mechanism: pantoprazole may interfere absorption drugs gastric pH important determinant bioavailability ( eg , ketoconazole\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "mechanism: pantoprazole may interfere absorption drugs gastric pH important determinant bioavailability ( eg , ketoconazole , ampicillin\n",
      "mechanism: pantoprazole may interfere absorption drugs gastric pH important determinant bioavailability ( eg , ketoconazole , ampicillin esters , iron\n",
      "effect: NSAIDs may diminish antihypertensive effect angiotensin-converting enzyme ( ACE ) inhibitors\n",
      "advise: NSAIDs concomitantly ACE inhibitors\n",
      "mechanism: aspirin ( 1000 mg TID ) healthy volunteers tended increase AUC ( 10 % ) Cmax ( 24 % ) meloxicam\n",
      "advise: NSAIDs , concomitant administration meloxicam aspirin\n",
      "advise: meloxicam aspirin\n",
      "effect: aspirin MOBIC\n",
      "mechanism: cholestyramine significantly increased clearance meloxicam\n",
      "effect: NSAIDs reduce natriuretic effect furosemide\n",
      "effect: NSAIDs reduce natriuretic effect furosemide thiazide diuretics\n",
      "advise: furosemide MOBIC\n",
      "mechanism: NSAIDs produced elevation plasma lithium\n",
      "mechanism: lithium doses ranging 804 1072 mg BID meloxicam\n",
      "advise: lithium treatment closely monitored MOBIC\n",
      "advise: MOBIC therapy patients receiving warfarin\n",
      "advise: MOBIC warfarin\n",
      "mechanism: mexiletine decreased 38 % following coadministration fluvoxamine\n",
      "mechanism: phenytoin hepatic enzyme inducers rifampin phenobarbital taken concurrently Mexitil\n",
      "mechanism: rifampin phenobarbital taken concurrently Mexitil\n",
      "mechanism: phenobarbital taken concurrently Mexitil\n",
      "mechanism: cimetidine Mexitil\n",
      "mechanism: magnesium-aluminum hydroxide , used treat gastrointestinal symptoms due Mexitil , reported lower serum digoxin\n",
      "mechanism: Mexitil theophylline\n",
      "mechanism: Theophylline plasma levels returned pre-Mexitil values within 48 hours discontinuing Mexitil\n",
      "advise: Mexitil theophylline\n",
      "mechanism: caffeine decreased 50 % following administration Mexitil\n",
      "effect: Ritalin may decrease hypotensive effect guanethidine\n",
      "mechanism: Ritalin may inhibit metabolism coumarin anticoagulants\n",
      "mechanism: Ritalin may inhibit metabolism coumarin anticoagulants , anticonvulsants\n",
      "mechanism: Ritalin may inhibit metabolism coumarin anticoagulants , anticonvulsants ( phenobarbital\n",
      "mechanism: Ritalin may inhibit metabolism coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin\n",
      "mechanism: Ritalin may inhibit metabolism coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone\n",
      "mechanism: Ritalin may inhibit metabolism coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone\n",
      "mechanism: Ritalin may inhibit metabolism coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , tricyclic drugs\n",
      "mechanism: Ritalin may inhibit metabolism coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , tricyclic drugs ( imipramine\n",
      "mechanism: Ritalin may inhibit metabolism coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , tricyclic drugs ( imipramine , clomipramine\n",
      "mechanism: Ritalin may inhibit metabolism coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , tricyclic drugs ( imipramine , clomipramine , desipramine\n",
      "advise: ZADAXIN therapy combination immunomodulating drugs\n",
      "effect: SKELAXIN may enhance effects alcohol\n",
      "effect: SKELAXIN may enhance effects alcohol , barbiturates\n",
      "effect: SKELAXIN may enhance effects alcohol , barbiturates CNS depressants\n",
      "advise: CHEMET chelation therapy , CaNa 2 EDTA\n",
      "mechanism: Alcohol - impairs intestinal absorption riboflavin\n",
      "mechanism: Probenecid - concurrent use decreases gastrointestinal absorption riboflavin\n",
      "effect: riboflavin may increased patients receiving probenecid\n",
      "effect: alcohol CNS depression-producing drugs may increase CNS depressant effects methyprylon\n",
      "effect: CNS depression-producing drugs may increase CNS depressant effects methyprylon\n",
      "mechanism: rimantadine HCl administered one hour initiation Cimetidine\n",
      "mechanism: acetaminophen reduced peak concentration AUC values rimantadine\n",
      "mechanism: rimantadine reduced approximately 10 % presence aspirin\n",
      "mechanism: XENICAL coadministered cyclosporine\n",
      "mechanism: beta-carotene supplement absorption concomitantly administered XENICAL\n",
      "mechanism: XENICAL inhibited absorption vitamin E acetate\n",
      "mechanism: vitamin K absorption may decreased XENICAL\n",
      "advise: warfarin prescribed XENICAL\n",
      "int: cholinesterase inhibitors potential interfere activity anticholinergic medications\n",
      "effect: cholinesterase inhibitors given concurrently succinylcholine\n",
      "effect: cholinesterase inhibitors given concurrently succinylcholine , similar neuromuscular blocking agents\n",
      "effect: cholinesterase inhibitors given concurrently succinylcholine , similar neuromuscular blocking agents cholinergic agonists\n",
      "effect: cholinesterase inhibitors given concurrently succinylcholine , similar neuromuscular blocking agents cholinergic agonists bethanechol\n",
      "mechanism: gemfibrozil ) may increase AUC rosiglitazone\n",
      "mechanism: rifampin ) may decrease AUC rosiglitazone\n",
      "mechanism: ZAVESCA appeared increase clearance Cerezyme\n",
      "advise: Cerezyme ( imiglucerase ) ZAVESCA\n",
      "advise: imiglucerase ) ZAVESCA\n",
      "effect: metoclopramide gastrointestinal motility antagonized anticholinergic drugs\n",
      "effect: metoclopramide gastrointestinal motility antagonized anticholinergic drugs narcotic analgesics\n",
      "effect: metoclopramide given alcohol\n",
      "effect: metoclopramide given alcohol , sedatives\n",
      "effect: metoclopramide given alcohol , sedatives , hypnotics\n",
      "effect: metoclopramide given alcohol , sedatives , hypnotics , narcotics\n",
      "effect: metoclopramide given alcohol , sedatives , hypnotics , narcotics , tranquilizers\n",
      "advise: metoclopramide releases catecholamines patients essential hypertension suggests used cautiously , , patients receiving monoamine oxi-dase inhibitors\n",
      "mechanism: digoxin ) metoclopramide\n",
      "mechanism: metoclopramide , whereas rate and/or extent absorption drugs small bowel may increased ( e.g. , acetaminophen\n",
      "advise: metoclopramide influence delivery food intestines thus rate absorption , insulin\n",
      "advise: mazindol taken monoamine oxidase inhibitor\n",
      "advise: mazindol taken monoamine oxidase inhibitor ( MAOI\n",
      "advise: mazindol taken monoamine oxidase inhibitor ( MAOI ) isocarboxazid\n",
      "advise: mazindol taken monoamine oxidase inhibitor ( MAOI ) isocarboxazid ( Marplan\n",
      "advise: mazindol taken monoamine oxidase inhibitor ( MAOI ) isocarboxazid ( Marplan ) , tranylcypromine\n",
      "advise: mazindol taken monoamine oxidase inhibitor ( MAOI ) isocarboxazid ( Marplan ) , tranylcypromine ( Parnate\n",
      "advise: mazindol taken monoamine oxidase inhibitor ( MAOI ) isocarboxazid ( Marplan ) , tranylcypromine ( Parnate ) , phenelzine\n",
      "advise: mazindol taken monoamine oxidase inhibitor ( MAOI ) isocarboxazid ( Marplan ) , tranylcypromine ( Parnate ) , phenelzine ( Nardil\n",
      "advise: insulin diabetes drug therapies may necessary treatment mazindol\n",
      "effect: Mazindol may reduce effects guanethidine\n",
      "effect: Mazindol may reduce effects guanethidine ( Ismelin\n",
      "advise: Celontin ( methsuximide ) may interact concurrently administered antiepileptic drugs\n",
      "advise: methsuximide ) may interact concurrently administered antiepileptic drugs\n",
      "mechanism: methsuximide may increase plasma concentrations phenytoin\n",
      "mechanism: methsuximide may increase plasma concentrations phenytoin phenobarbital\n",
      "effect: lorazepam pyrimethamine\n",
      "advise: NEXAVAR compounds metabolized/eliminated predominantly UGT1A1 pathway ( e.g . irinotecan\n",
      "mechanism: NEXAVAR resulted 21 % increase AUC doxorubicin\n",
      "advise: doxorubicin NEXAVAR\n",
      "effect: Anticholinergics medications anticholinergic activity used concurrently opioid analgesics\n",
      "effect: oxymorphone combined propofol\n",
      "effect: cimetidine opioid analgesics\n",
      "mechanism: Streptozocin reported prolong elimination half-life doxorubicin\n",
      "advise: doxorubicin dosage considered patients receiving ZANOSAR\n",
      "effect: streptozocin phenytoin\n",
      "effect: selegiline meperidine\n",
      "int: meperidine MAOIs\n",
      "effect: tricyclic antidepressants ELDEPRYL\n",
      "effect: selective serotonin reuptake inhibitors ELDEPRYL\n",
      "effect: selegiline sympathomimetic medication\n",
      "effect: selegiline sympathomimetic medication ( ephedrine\n",
      "int: Barbiturates may decrease effectiveness oral contraceptives\n",
      "int: Barbiturates may decrease effectiveness oral contraceptives , certain antibiotics\n",
      "int: Barbiturates may decrease effectiveness oral contraceptives , certain antibiotics , quinidine\n",
      "int: Barbiturates may decrease effectiveness oral contraceptives , certain antibiotics , quinidine , theophylline\n",
      "int: Barbiturates may decrease effectiveness oral contraceptives , certain antibiotics , quinidine , theophylline , corticosteroids\n",
      "int: Barbiturates may decrease effectiveness oral contraceptives , certain antibiotics , quinidine , theophylline , corticosteroids , anticoagulants\n",
      "int: Barbiturates may decrease effectiveness oral contraceptives , certain antibiotics , quinidine , theophylline , corticosteroids , anticoagulants , beta blockers\n",
      "int: Vindesine interact drugs following categories : - Blood dyscrasia : cause unpredictable myelotoxicity - Bone marrow depressants : cause predictable dose-related myelotoxicity - Radiation therapy : may cause marrow depression - Neurotoxic medications : cause neurologic toxicity - Phenytoin\n",
      "int: Vindesine interact drugs following categories : - Blood dyscrasia : cause unpredictable myelotoxicity - Bone marrow depressants : cause predictable dose-related myelotoxicity - Radiation therapy : may cause marrow depression - Neurotoxic medications : cause neurologic toxicity - Phenytoin : increase seizure activity - Live virus vaccines\n",
      "int: Vindesine interact drugs following categories : - Blood dyscrasia : cause unpredictable myelotoxicity - Bone marrow depressants : cause predictable dose-related myelotoxicity - Radiation therapy : may cause marrow depression - Neurotoxic medications : cause neurologic toxicity - Phenytoin : increase seizure activity - Live virus vaccines : may potentiate replication vaccine virus , may increase side effects vaccination , decrease patient 's response vaccine - Mitomycin-C\n",
      "int: Vindesine interact drugs following categories : - Blood dyscrasia : cause unpredictable myelotoxicity - Bone marrow depressants : cause predictable dose-related myelotoxicity - Radiation therapy : may cause marrow depression - Neurotoxic medications : cause neurologic toxicity - Phenytoin : increase seizure activity - Live virus vaccines : may potentiate replication vaccine virus , may increase side effects vaccination , decrease patient 's response vaccine - Mitomycin-C : may cause shortness breath bronchospasm - Killed virus vaccines\n",
      "mechanism: methadone , treatment PEG-Intron\n",
      "effect: heparin vitamin K antagonists , drugs alter platelet function ( aspirin , dipyridamole , abciximab ) may increase risk bleeding administered prior Retavase\n",
      "effect: vitamin K antagonists , drugs alter platelet function ( aspirin , dipyridamole , abciximab ) may increase risk bleeding administered prior Retavase\n",
      "effect: aspirin , dipyridamole , abciximab ) may increase risk bleeding administered prior Retavase\n",
      "effect: dipyridamole , abciximab ) may increase risk bleeding administered prior Retavase\n",
      "effect: abciximab ) may increase risk bleeding administered prior Retavase\n",
      "mechanism: digoxin co-administration 100 mg sitagliptin\n",
      "mechanism: Cimetidine , known inhibitor renal tubular secretion organic bases via cationic transport system , caused 50 % increase pramipexole\n",
      "mechanism: cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , quinine ) decreases oral clearance pramipexole\n",
      "mechanism: ranitidine , diltiazem , triamterene , verapamil , quinidine , quinine ) decreases oral clearance pramipexole\n",
      "mechanism: diltiazem , triamterene , verapamil , quinidine , quinine ) decreases oral clearance pramipexole\n",
      "mechanism: triamterene , verapamil , quinidine , quinine ) decreases oral clearance pramipexole\n",
      "mechanism: verapamil , quinidine , quinine ) decreases oral clearance pramipexole\n",
      "mechanism: quinidine , quinine ) decreases oral clearance pramipexole\n",
      "mechanism: quinine ) decreases oral clearance pramipexole\n",
      "mechanism: cephalosporins , penicillins , indomethacin , hydrochlorothiazide , chlorpropamide ) likely little effect oral clearance pramipexole\n",
      "mechanism: penicillins , indomethacin , hydrochlorothiazide , chlorpropamide ) likely little effect oral clearance pramipexole\n",
      "mechanism: indomethacin , hydrochlorothiazide , chlorpropamide ) likely little effect oral clearance pramipexole\n",
      "mechanism: hydrochlorothiazide , chlorpropamide ) likely little effect oral clearance pramipexole\n",
      "mechanism: chlorpropamide ) likely little effect oral clearance pramipexole\n",
      "effect: dopamine antagonists , neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) metoclopramide , may diminish effectiveness MIRAPEX\n",
      "effect: neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) metoclopramide , may diminish effectiveness MIRAPEX\n",
      "effect: phenothiazines , butyrophenones , thioxanthenes ) metoclopramide , may diminish effectiveness MIRAPEX\n",
      "effect: butyrophenones , thioxanthenes ) metoclopramide , may diminish effectiveness MIRAPEX\n",
      "effect: thioxanthenes ) metoclopramide , may diminish effectiveness MIRAPEX\n",
      "effect: metoclopramide , may diminish effectiveness MIRAPEX\n",
      "advise: SYMLIN therapy considered patients taking drugs alter gastrointestinal motility ( e.g. , anticholinergic agents\n",
      "advise: SYMLIN therapy considered patients taking drugs alter gastrointestinal motility ( e.g. , anticholinergic agents atropine\n",
      "advise: SYMLIN therapy considered patients taking drugs alter gastrointestinal motility ( e.g. , anticholinergic agents atropine ) agents slow intestinal absorption nutrients ( e.g. , alpha glucosidase inhibitors\n",
      "advise: analgesics ) , agent administered least 1 hour prior 2 hours SYMLIN\n",
      "mechanism: SYMLIN altered mixed regular , NPH , 70/30 premixed formulations recombinant human insulin\n",
      "effect: ZOLINZA concomitantly coumarin-derivative anticoagulants\n",
      "advise: ZOLINZA coumarin derivatives\n",
      "effect: ZOLINZA HDAC inhibitors\n",
      "effect: ZOLINZA HDAC inhibitors ( e.g. , valproic acid\n",
      "effect: atropine pralidoxime\n",
      "effect: barbiturates potentiated anticholinesterases\n",
      "mechanism: Metopirone accelerated phenytoin\n",
      "mechanism: Metopirone inhibits glucuronidation acetaminophen\n",
      "effect: Metopirone inhibits glucuronidation acetaminophen could possibly potentiate acetaminophen\n",
      "effect: TOBI concomitantly dornase alfa\n",
      "effect: TOBI concomitantly dornase alfa ( PULMOZYME\n",
      "effect: TOBI concomitantly dornase alfa ( PULMOZYME , Genentech ) , ( beta ) -agonists\n",
      "effect: TOBI concomitantly dornase alfa ( PULMOZYME , Genentech ) , ( beta ) -agonists , inhaled corticosteroids\n",
      "effect: TOBI concomitantly dornase alfa ( PULMOZYME , Genentech ) , ( beta ) -agonists , inhaled corticosteroids , anti-pseudomonal antibiotics\n",
      "effect: TOBI concomitantly dornase alfa ( PULMOZYME , Genentech ) , ( beta ) -agonists , inhaled corticosteroids , anti-pseudomonal antibiotics , parenteral aminoglycosides\n",
      "effect: diuretics enhance aminoglycoside\n",
      "advise: TOBI administered concomitantly ethacrynic acid\n",
      "advise: TOBI administered concomitantly ethacrynic acid , furosemide\n",
      "advise: TOBI administered concomitantly ethacrynic acid , furosemide , urea\n",
      "advise: TOBI administered concomitantly ethacrynic acid , furosemide , urea , mannitol\n",
      "effect: Sulfamethizole may increase effects barbiturates\n",
      "effect: Sulfamethizole may increase effects barbiturates , tolbutamide\n",
      "effect: Sulfamethizole may increase effects barbiturates , tolbutamide , uricosurics\n",
      "effect: Anabolic steroids may increase sensitivity oral anticoagulants\n",
      "mechanism: oxandrolone , given 5 10 mg BID 15 healthy subjects concurrently treated warfarin\n",
      "advise: oxandrolone therapy initiated patient already receiving treatment warfarin\n",
      "advise: warfarin dosage indicated recommended oxandrolone\n",
      "mechanism: Oxandrolone may inhibit metabolism oral hypoglycemic agents\n",
      "advise: insulin and/or oral hypoglycemic agents may require dose reductions therapeutic agents initiation therapy SOMAVERT\n",
      "advise: hypoglycemic agents may require dose reductions therapeutic agents initiation therapy SOMAVERT\n",
      "mechanism: opioids often needed higher serum pegvisomant\n",
      "effect: vancomycin anesthetic agents\n",
      "mechanism: GH treatment increases cytochrome P450 ( CP450 ) mediated antipyrine\n",
      "mechanism: GH administration may alter clearance compounds known metabolized CP450 liver enzymes ( e.g. , corticosteroids\n",
      "mechanism: GH administration may alter clearance compounds known metabolized CP450 liver enzymes ( e.g. , corticosteroids , sex steroids\n",
      "mechanism: GH administration may alter clearance compounds known metabolized CP450 liver enzymes ( e.g. , corticosteroids , sex steroids , anticonvulsants\n",
      "mechanism: GH administration may alter clearance compounds known metabolized CP450 liver enzymes ( e.g. , corticosteroids , sex steroids , anticonvulsants , cyclosporin\n",
      "effect: digitalis sympathomimetic amines\n",
      "effect: Monoamine oxidase inhibitors tricyclic antidepressants may potentiate action sympathomimetic amines\n",
      "effect: tricyclic antidepressants may potentiate action sympathomimetic amines\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "advise: Scopolamine used care patients taking drugs capable causing CNS effects sedatives\n",
      "advise: Scopolamine used care patients taking drugs capable causing CNS effects sedatives , tranquilizers\n",
      "advise: Scopolamine used care patients taking drugs capable causing CNS effects sedatives , tranquilizers , alcohol\n",
      "effect: ASPIRIN AND OTHER SALICYLATE DRUGS WILL BE ADDITIVE TO DISALCID\n",
      "effect: SALICYLATE DRUGS WILL BE ADDITIVE TO DISALCID\n",
      "effect: Salicylates given concomitantly anticoagulant drugs\n",
      "effect: Salicylates may enhance hypoglycemic effect oral antidiabetic drugs\n",
      "mechanism: Salicylate competes number drugs protein binding sites , notably penicillin\n",
      "mechanism: Salicylate competes number drugs protein binding sites , notably penicillin , thiopental\n",
      "mechanism: Salicylate competes number drugs protein binding sites , notably penicillin , thiopental , thyroxine\n",
      "mechanism: Salicylate competes number drugs protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine\n",
      "mechanism: Salicylate competes number drugs protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin\n",
      "mechanism: Salicylate competes number drugs protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone\n",
      "mechanism: Salicylate competes number drugs protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen\n",
      "mechanism: Salicylate competes number drugs protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin\n",
      "mechanism: Salicylate competes number drugs protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate\n",
      "mechanism: Salicylate competes number drugs protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , possibly corticosteroids\n",
      "advise: ergotamine-containing ergot-type medications ( like dihydroergotamine methysergide ) sumatriptan\n",
      "advise: ergot-type medications ( like dihydroergotamine methysergide ) sumatriptan\n",
      "advise: dihydroergotamine methysergide ) sumatriptan\n",
      "advise: methysergide ) sumatriptan\n",
      "mechanism: MAO-A inhibitors reduce sumatriptan\n",
      "advise: sumatriptan succinate tablets patients receiving MAO-A inhibitors\n",
      "effect: Selective serotonin reuptake inhibitors ( SSRIs ) ( e.g. , fluoxetine , fluvoxamine , paroxetine , sertraline ) reported , rarely , cause weakness , hyperreflexia , incoordination coadministered sumatriptan\n",
      "effect: SSRIs ) ( e.g. , fluoxetine , fluvoxamine , paroxetine , sertraline ) reported , rarely , cause weakness , hyperreflexia , incoordination coadministered sumatriptan\n",
      "effect: fluoxetine , fluvoxamine , paroxetine , sertraline ) reported , rarely , cause weakness , hyperreflexia , incoordination coadministered sumatriptan\n",
      "effect: fluvoxamine , paroxetine , sertraline ) reported , rarely , cause weakness , hyperreflexia , incoordination coadministered sumatriptan\n",
      "effect: paroxetine , sertraline ) reported , rarely , cause weakness , hyperreflexia , incoordination coadministered sumatriptan\n",
      "effect: sertraline ) reported , rarely , cause weakness , hyperreflexia , incoordination coadministered sumatriptan\n",
      "advise: sumatriptan SSRI\n",
      "effect: Thiazides may decrease arterial responsiveness norepinephrine\n",
      "effect: Thiazide drugs may increase responsiveness tubocurarine\n",
      "mechanism: Lithium renal clearance reduced thiazides\n",
      "effect: Thiazides may add potentiate action antihypertensive drugs\n",
      "mechanism: paclitaxel combination HERCEPTIN\n",
      "effect: metronidazole reported potentiate anticoagulant effect coumarin\n",
      "effect: metronidazole reported potentiate anticoagulant effect coumarin warfarin\n",
      "effect: Vasopressors , particularly metaraminol , may cause serious cardiac arrhythmias halothane\n",
      "effect: metaraminol , may cause serious cardiac arrhythmias halothane\n",
      "effect: sympathomimetic pressor amines markedly potentiated patients receiving monoamine oxidase inhibitors\n",
      "effect: sympathomimetic pressor amines markedly potentiated patients receiving monoamine oxidase inhibitors ( MAOI\n",
      "effect: adrenergic agents may also potentiated tricyclic antidepressants\n",
      "effect: MAO inhibitors beta adrenergic blockers increase effects pseudoephedrine\n",
      "effect: beta adrenergic blockers increase effects pseudoephedrine\n",
      "effect: Sympathomimetics may reduce antihypertensive effects methyldopa\n",
      "effect: Sympathomimetics may reduce antihypertensive effects methyldopa , mecamylamine\n",
      "effect: Sympathomimetics may reduce antihypertensive effects methyldopa , mecamylamine , reserpine\n",
      "effect: Sympathomimetics may reduce antihypertensive effects methyldopa , mecamylamine , reserpine veratrum alkaloids\n",
      "effect: AGGRASTAT , combination heparin\n",
      "effect: AGGRASTAT , combination heparin aspirin\n",
      "effect: opioids reduced approximately half , levomepromazine\n",
      "effect: levomepromazine amplifies therapeutic actions side-effects opioids\n",
      "effect: levomepromazine given benzodiazepines\n",
      "effect: levomepromazine given benzodiazepines barbiturates\n",
      "advise: levomepromazine anticholinergic drugs\n",
      "advise: levomepromazine anticholinergic drugs ( tricyclic antidepressants\n",
      "advise: levomepromazine anticholinergic drugs ( tricyclic antidepressants antiparkinsonian-agents\n",
      "effect: Caffeine and/or stimulantes ephedrine/amphetamine type may counteract specific actions levomepromazine\n",
      "effect: ephedrine/amphetamine type may counteract specific actions levomepromazine\n",
      "effect: type may counteract specific actions levomepromazine\n",
      "advise: lithium Neulasta\n"
     ]
    }
   ],
   "source": [
    "save_info = {}\n",
    "save_count = {}\n",
    "def dump_data(datadir):\n",
    "\n",
    "    # process each file in directory\n",
    "    for f in listdir(datadir) :\n",
    "        # parse XML file, obtaining a DOM tree\n",
    "        tree = parse(datadir+\"/\"+f)\n",
    "        # process each sentence in the file\n",
    "        sentences = tree.getElementsByTagName(\"sentence\")\n",
    "        for s in sentences :\n",
    "            sid = s.attributes[\"id\"].value\n",
    "             # get sentence id\n",
    "            stext = s.attributes[\"text\"].value # get sentence text\n",
    "            tokens = tokenize(stext)\n",
    "            # load and store sentence entities\n",
    "            entities = {}\n",
    "            ents = s.getElementsByTagName(\"entity\")\n",
    "            for e in ents :\n",
    "                id = e.attributes[\"id\"].value\n",
    "                offs = e.attributes[\"charOffset\"].value.split(\"-\")\n",
    "                entities[id] = offs\n",
    "            # for each pair in the sentence, extract entities\n",
    "            # and words in between\n",
    "            pairs = s.getElementsByTagName(\"pair\")\n",
    "            for p in pairs:\n",
    "                id_e1 = p.attributes[\"e1\"].value\n",
    "                id_e2 = p.attributes[\"e2\"].value\n",
    "                ddi = p.attributes[\"ddi\"].value\n",
    "                if ddi==\"true\" and \"type\" in p.attributes:\n",
    "                    \n",
    "                    e1_start = int(entities[id_e1][0])\n",
    "                    e2_end = int(entities[id_e2][-1])\n",
    "                    print (p.attributes[\"type\"].value+\":\", end=\"\")\n",
    "                    name = p.attributes[\"type\"].value\n",
    "                    for t in tokens :\n",
    "                        if t[0] in stopwords:\n",
    "                            continue\n",
    "                        if t[0].isalpha():\n",
    "                            try:\n",
    "                                save_info[name].append(t[0])\n",
    "                                save_count[name] +=1\n",
    "                            except:\n",
    "                                save_info[name] = []\n",
    "                                save_count[name] = 0\n",
    "                        if (t[1]>=e1_start and t[2]<=e2_end):\n",
    "                            print (\" \"+t[0], end=\"\")\n",
    "                    print(\"\")\n",
    "\n",
    "dump_data(datadir)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'mechanism': 4974, 'effect': 5014, 'advise': 3743, 'int': 2423}\n",
      "mechanism \n",
      " [('may', 115), ('drugs', 93), ('clearance', 82), ('phenytoin', 55), ('increase', 52), ('plasma', 51), ('metabolism', 51), ('concentrations', 50), ('levels', 49), ('ketoconazole', 42), ('secretion', 41), ('system', 39), ('AUC', 37), ('phenobarbital', 35), ('oral', 35), ('pharmacokinetic', 34), ('administered', 33), ('increased', 32), ('renal', 29), ('itraconazole', 29)]\n",
      "effect \n",
      " [('may', 180), ('effects', 106), ('drugs', 100), ('agents', 93), ('The', 71), ('inhibitors', 65), ('patients', 60), ('increase', 56), ('effect', 42), ('administered', 40), ('concomitantly', 39), ('use', 38), ('anticholinergic', 37), ('alcohol', 35), ('bleeding', 31), ('reported', 29), ('activity', 29), ('blocking', 28), ('meperidine', 28), ('CNS', 26)]\n",
      "advise \n",
      " [('patients', 63), ('drugs', 60), ('ketoconazole', 49), ('may', 44), ('recommended', 41), ('administered', 38), ('receiving', 36), ('inhibitors', 36), ('dose', 33), ('paricalcitol', 33), ('used', 32), ('administration', 28), ('OTHER', 27), ('itraconazole', 25), ('clarithromycin', 25), ('agents', 23), ('effects', 23), ('eg', 23), ('strong', 23), ('concomitantly', 22)]\n",
      "int \n",
      " [('may', 120), ('quinidine', 56), ('drugs', 49), ('interact', 44), ('melatonin', 40), ('certain', 35), ('antibiotics', 35), ('corticosteroids', 31), ('sodium', 30), ('action', 29), ('Other', 28), ('enhance', 28), ('neuromuscular', 28), ('blocking', 28), ('nondepolarizing', 28), ('agents', 28), ('MIVACRON', 28), ('include', 28), ('aminoglycosides', 28), ('tetracyclines', 28)]\n"
     ]
    }
   ],
   "source": [
    "from collections import Counter\n",
    "print(save_count)\n",
    "for k in save_info:\n",
    "    print(k, '\\n',Counter(save_info[k]).most_common()[:20])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "train_df = pd.read_csv(train_df_path, index_col=0)\n",
    "from sklearn.feature_extraction.text import CountVectorizer\n",
    "\n",
    "\n",
    "sentences = train_df.sentence_text.values\n",
    "y = train_df['relation_type'].values\n",
    "\n",
    "from sklearn.model_selection import train_test_split\n",
    "\n",
    "sentences_train, sentences_val, y_train, y_val = train_test_split(sentences, y, test_size=0.25, random_state=1000, stratify=y)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "scrolled": false
   },
   "outputs": [],
   "source": [
    "from sklearn.linear_model import LogisticRegression\n",
    "\n",
    "classifier = LogisticRegression()\n",
    "classifier.fit(X_train, y_train)\n",
    "y_pred = classifier.predict(X_val)\n",
    "\n",
    "df_confusion = pd.crosstab(y_val, y_pred)\n",
    "\n",
    "score = classifier.score(X_val, y_val)\n",
    "print(\"Accuracy:\", score)\n",
    "df_confusion"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [
    {
     "ename": "NameError",
     "evalue": "name 'train_df_path' is not defined",
     "output_type": "error",
     "traceback": [
      "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[0;31mNameError\u001b[0m                                 Traceback (most recent call last)",
      "\u001b[0;32m<ipython-input-9-a447c8d233e4>\u001b[0m in \u001b[0;36m<module>\u001b[0;34m\u001b[0m\n\u001b[0;32m----> 1\u001b[0;31m \u001b[0mtrain_df\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mpd\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mread_csv\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mtrain_df_path\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mindex_col\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0;36m0\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m",
      "\u001b[0;31mNameError\u001b[0m: name 'train_df_path' is not defined"
     ]
    }
   ],
   "source": [
    " train_df = pd.read_csv(train_df_path, index_col=0)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [
    {
     "ename": "SyntaxError",
     "evalue": "unexpected EOF while parsing (<ipython-input-8-6040ebbe3c13>, line 2)",
     "output_type": "error",
     "traceback": [
      "\u001b[0;36m  File \u001b[0;32m\"<ipython-input-8-6040ebbe3c13>\"\u001b[0;36m, line \u001b[0;32m2\u001b[0m\n\u001b[0;31m    \u001b[0m\n\u001b[0m    ^\u001b[0m\n\u001b[0;31mSyntaxError\u001b[0m\u001b[0;31m:\u001b[0m unexpected EOF while parsing\n"
     ]
    }
   ],
   "source": [
    "def pre_processing(sentences_train):\n",
    "    pass"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 116,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Counter({'none': 23771, 'effect': 1687, 'mechanism': 1319, 'advise': 826, 'int': 188})\n"
     ]
    }
   ],
   "source": [
    "def train_baseline():\n",
    "    train_df = pd.read_csv(train_df_path, index_col=0)\n",
    "    sentences_train = train_df.sentence_text.values\n",
    "    \n",
    "    y_train = train_df['relation_type'].values\n",
    "    print(Counter(y_train))\n",
    "    vectorizer = CountVectorizer()\n",
    "    vectorizer.fit(sentences_train)\n",
    "    X_train = vectorizer.transform(sentences_train)\n",
    "    classifier = LogisticRegression()\n",
    "    classifier.fit(X_train, y_train)\n",
    "    return vectorizer, classifier\n",
    "\n",
    "vectorizer, classifier = train_baseline()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 121,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "SCORES FOR THE GROUP: raquel RUN=5\n",
      "Gold Dataset: /All\n",
      "\n",
      "Partial Evaluation: only detection of DDI (regadless to the type)\n",
      "tp\tfp\tfn\ttotal\tprec\trecall\tF1\n",
      "241\t528\t643\t884\t0.3134\t0.2726\t0.2916\n",
      "\n",
      "\n",
      "Detection and Classification of DDI\n",
      "tp\tfp\tfn\ttotal\tprec\trecall\tF1\n",
      "212\t557\t672\t884\t0.2757\t0.2398\t0.2565\n",
      "\n",
      "\n",
      "________________________________________________________________________\n",
      "\n",
      "SCORES FOR DDI TYPE\n",
      "Scores for ddi with type mechanism\n",
      "tp\tfp\tfn\ttotal\tprec\trecall\tF1\n",
      "42\t132\t260\t302\t0.2414\t0.1391\t0.1765\n",
      "\n",
      "\n",
      "Scores for ddi with type effect\n",
      "tp\tfp\tfn\ttotal\tprec\trecall\tF1\n",
      "100\t337\t260\t360\t0.2288\t0.2778\t0.2509\n",
      "\n",
      "\n",
      "Scores for ddi with type advise\n",
      "tp\tfp\tfn\ttotal\tprec\trecall\tF1\n",
      "70\t88\t151\t221\t0.443\t0.3167\t0.3694\n",
      "\n",
      "\n",
      "Scores for ddi with type int\n",
      "tp\tfp\tfn\ttotal\tprec\trecall\tF1\n",
      "0\t0\t96\t96\t0\t0\t0\n",
      "\n",
      "\n",
      "MACRO-AVERAGE MEASURES:\n",
      "\tP\tR\tF1\n",
      "\t0.2283\t0.1834\t0.2034\n",
      "________________________________________________________________________\n",
      "\n",
      "\n"
     ]
    }
   ],
   "source": [
    "def check_interaction(tokens, entities, e1, e2):\n",
    "    # uses the vectorizer and the classifier already trained\n",
    "    sentence_array = vectorizer.transform([tokens])\n",
    "    y_pred = classifier.predict(sentence_array)\n",
    "\n",
    "    if y_pred[0] == 'none':\n",
    "        return False, \"null\"\n",
    "    else:\n",
    "        return True, y_pred[0]\n",
    "\n",
    "def predict(datadir,output_path,test=False):\n",
    "    # process each file in directory\n",
    "    with open(output_path, 'w') as file:\n",
    "        for f in listdir(datadir):\n",
    "\n",
    "            # parse XML file, obtaining a DOM tree\n",
    "            tree = parse(datadir + \"/\" + f)\n",
    "\n",
    "            # process each sentence in the file\n",
    "            sentences = tree.getElementsByTagName(\"sentence\")\n",
    "            for s in sentences:\n",
    "                sid = s.attributes[\"id\"].value  # get sentence id\n",
    "                stext = s.attributes[\"text\"].value  # get sentence text\n",
    "\n",
    "                # load sentence entities\n",
    "                entities = {}\n",
    "                ents = s.getElementsByTagName(\"entity\")\n",
    "                for e in ents:\n",
    "                    id = e.attributes[\"id\"].value\n",
    "                    offs = e.attributes[\"charOffset\"].value.split(\"-\")\n",
    "                    entities[id] = offs\n",
    "\n",
    "                # for each pair in the sentence, decide whether it is DDI and its type\n",
    "                pairs = s.getElementsByTagName(\"pair\")\n",
    "                for p in pairs:\n",
    "                    id_e1 = p.attributes[\"e1\"].value\n",
    "                    id_e2 = p.attributes[\"e2\"].value\n",
    "                    (is_ddi, ddi_type) = check_interaction(stext, entities, id_e1, id_e2)                    \n",
    "                    ddi = \"1\" if is_ddi else \"0\"\n",
    "                    file.write(sid + \"|\" + id_e1 + \"|\" + id_e2 + \"|\" + ddi + \"|\" + ddi_type)\n",
    "                    file.write('\\n')\n",
    "                    if test:\n",
    "                        return\n",
    "\n",
    "def show_results(results_path):\n",
    "    import subprocess\n",
    "    subprocess.call(['java', '-jar', '../../eval/evaluateDDI.jar', '../../data/Test-DDI/All', output_path])\n",
    "    results_file = open(results_path,'r')\n",
    "    print(results_file.read())\n",
    "    results_file.close()\n",
    "\n",
    "predict(datadir,output_path,False)\n",
    "show_results(results_path)"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "ahlt",
   "language": "python",
   "name": "ahlt"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.6.7"
  },
  "toc": {
   "base_numbering": 1,
   "nav_menu": {},
   "number_sections": true,
   "sideBar": true,
   "skip_h1_title": false,
   "title_cell": "Table of Contents",
   "title_sidebar": "Contents",
   "toc_cell": false,
   "toc_position": {},
   "toc_section_display": true,
   "toc_window_display": false
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
